WO2023009708A1 - Hétéroaryloxy triazolo-azines et imidazo-azines en tant qu'inhibiteurs de jak2 - Google Patents
Hétéroaryloxy triazolo-azines et imidazo-azines en tant qu'inhibiteurs de jak2 Download PDFInfo
- Publication number
- WO2023009708A1 WO2023009708A1 PCT/US2022/038654 US2022038654W WO2023009708A1 WO 2023009708 A1 WO2023009708 A1 WO 2023009708A1 US 2022038654 W US2022038654 W US 2022038654W WO 2023009708 A1 WO2023009708 A1 WO 2023009708A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- optionally substituted
- nitrogen
- sulfur
- oxygen
- independently selected
- Prior art date
Links
- 125000005553 heteroaryloxy group Chemical group 0.000 title abstract 2
- 229940121730 Janus kinase 2 inhibitor Drugs 0.000 title description 6
- 239000000203 mixture Substances 0.000 claims abstract description 48
- 102100033444 Tyrosine-protein kinase JAK2 Human genes 0.000 claims abstract description 31
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 5
- 101000997832 Homo sapiens Tyrosine-protein kinase JAK2 Proteins 0.000 claims abstract 3
- 229910052757 nitrogen Inorganic materials 0.000 claims description 289
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 282
- 125000005842 heteroatom Chemical group 0.000 claims description 268
- 150000001875 compounds Chemical class 0.000 claims description 264
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 256
- 229910052717 sulfur Chemical group 0.000 claims description 256
- 239000011593 sulfur Chemical group 0.000 claims description 256
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 255
- 229910052760 oxygen Inorganic materials 0.000 claims description 255
- 239000001301 oxygen Chemical group 0.000 claims description 255
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 251
- 229920006395 saturated elastomer Polymers 0.000 claims description 208
- 125000001931 aliphatic group Chemical group 0.000 claims description 125
- 229910052739 hydrogen Inorganic materials 0.000 claims description 59
- 239000001257 hydrogen Substances 0.000 claims description 59
- 125000000217 alkyl group Chemical group 0.000 claims description 55
- 238000000034 method Methods 0.000 claims description 49
- 229910052736 halogen Inorganic materials 0.000 claims description 47
- 150000002367 halogens Chemical group 0.000 claims description 41
- 125000003118 aryl group Chemical group 0.000 claims description 37
- 150000003839 salts Chemical class 0.000 claims description 37
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 36
- 125000002618 bicyclic heterocycle group Chemical group 0.000 claims description 35
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 33
- 125000004452 carbocyclyl group Chemical group 0.000 claims description 32
- 229910052720 vanadium Inorganic materials 0.000 claims description 30
- 150000002431 hydrogen Chemical group 0.000 claims description 27
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 25
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 18
- 125000002619 bicyclic group Chemical group 0.000 claims description 17
- 229910052799 carbon Inorganic materials 0.000 claims description 17
- 201000010099 disease Diseases 0.000 claims description 17
- 208000035475 disorder Diseases 0.000 claims description 16
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 16
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 15
- 125000000623 heterocyclic group Chemical group 0.000 claims description 12
- 125000002950 monocyclic group Chemical group 0.000 claims description 10
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 9
- 206010066476 Haematological malignancy Diseases 0.000 claims description 8
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 201000007224 Myeloproliferative neoplasm Diseases 0.000 claims description 7
- 206010028980 Neoplasm Diseases 0.000 claims description 6
- 201000011510 cancer Diseases 0.000 claims description 6
- 125000006645 (C3-C4) cycloalkyl group Chemical group 0.000 claims description 4
- 229910052721 tungsten Inorganic materials 0.000 claims description 4
- 229910052727 yttrium Inorganic materials 0.000 claims description 4
- 208000017733 acquired polycythemia vera Diseases 0.000 claims description 3
- 208000037244 polycythemia vera Diseases 0.000 claims description 3
- 206010043554 thrombocytopenia Diseases 0.000 claims description 3
- 206010025323 Lymphomas Diseases 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 208000032839 leukemia Diseases 0.000 claims description 2
- 206010028537 myelofibrosis Diseases 0.000 claims description 2
- 125000001183 hydrocarbyl group Chemical group 0.000 claims 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 102
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 87
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 78
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 60
- 239000011541 reaction mixture Substances 0.000 description 48
- 230000015572 biosynthetic process Effects 0.000 description 46
- 238000003786 synthesis reaction Methods 0.000 description 45
- 239000000243 solution Substances 0.000 description 37
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 32
- 210000004027 cell Anatomy 0.000 description 32
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 30
- 238000003818 flash chromatography Methods 0.000 description 29
- 239000000741 silica gel Substances 0.000 description 29
- 229910002027 silica gel Inorganic materials 0.000 description 29
- 108010019437 Janus Kinase 2 Proteins 0.000 description 28
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 28
- 239000012267 brine Substances 0.000 description 28
- 239000012044 organic layer Substances 0.000 description 28
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 28
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 24
- 125000001153 fluoro group Chemical group F* 0.000 description 22
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 20
- -1 bicyclic hydrocarbon Chemical class 0.000 description 20
- 230000008569 process Effects 0.000 description 19
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 18
- 125000001309 chloro group Chemical group Cl* 0.000 description 18
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 17
- 238000003556 assay Methods 0.000 description 17
- CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 16
- 125000001424 substituent group Chemical group 0.000 description 16
- 238000012360 testing method Methods 0.000 description 16
- 150000002430 hydrocarbons Chemical group 0.000 description 15
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 15
- 229910001868 water Inorganic materials 0.000 description 15
- 239000011550 stock solution Substances 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- 239000005457 ice water Substances 0.000 description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- 125000001246 bromo group Chemical group Br* 0.000 description 12
- 125000001072 heteroaryl group Chemical group 0.000 description 12
- 239000003446 ligand Substances 0.000 description 12
- 108091000080 Phosphotransferase Proteins 0.000 description 11
- 125000002015 acyclic group Chemical group 0.000 description 11
- 238000009739 binding Methods 0.000 description 11
- 239000000872 buffer Substances 0.000 description 11
- 150000001721 carbon Chemical group 0.000 description 11
- 102000020233 phosphotransferase Human genes 0.000 description 11
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 10
- 239000011324 bead Substances 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 10
- 229910052786 argon Inorganic materials 0.000 description 9
- 230000027455 binding Effects 0.000 description 9
- 230000005587 bubbling Effects 0.000 description 9
- 125000005843 halogen group Chemical group 0.000 description 9
- 229930195733 hydrocarbon Natural products 0.000 description 9
- 239000004215 Carbon black (E152) Substances 0.000 description 8
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 8
- 229920001213 Polysorbate 20 Polymers 0.000 description 8
- 239000012300 argon atmosphere Substances 0.000 description 8
- 125000004432 carbon atom Chemical group C* 0.000 description 8
- 238000001514 detection method Methods 0.000 description 8
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 8
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 8
- CXNIUSPIQKWYAI-UHFFFAOYSA-N xantphos Chemical compound C=12OC3=C(P(C=4C=CC=CC=4)C=4C=CC=CC=4)C=CC=C3C(C)(C)C2=CC=CC=1P(C=1C=CC=CC=1)C1=CC=CC=C1 CXNIUSPIQKWYAI-UHFFFAOYSA-N 0.000 description 8
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 7
- 239000007995 HEPES buffer Substances 0.000 description 7
- 239000012981 Hank's balanced salt solution Substances 0.000 description 7
- 239000013543 active substance Substances 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- 239000003112 inhibitor Substances 0.000 description 7
- 239000000523 sample Substances 0.000 description 7
- 239000011534 wash buffer Substances 0.000 description 7
- 239000012224 working solution Substances 0.000 description 7
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 6
- 239000006180 TBST buffer Substances 0.000 description 6
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 6
- 229910000024 caesium carbonate Inorganic materials 0.000 description 6
- 150000004696 coordination complex Chemical class 0.000 description 6
- 239000002552 dosage form Substances 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 210000003494 hepatocyte Anatomy 0.000 description 6
- 238000011534 incubation Methods 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 239000013641 positive control Substances 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 238000000159 protein binding assay Methods 0.000 description 6
- 238000011282 treatment Methods 0.000 description 6
- 238000001665 trituration Methods 0.000 description 6
- 101000767160 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) Intracellular protein transport protein USO1 Proteins 0.000 description 5
- 125000002947 alkylene group Chemical group 0.000 description 5
- 238000000502 dialysis Methods 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 4
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 description 4
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 4
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 4
- 102000042838 JAK family Human genes 0.000 description 4
- 108091082332 JAK family Proteins 0.000 description 4
- 101100446506 Mus musculus Fgf3 gene Proteins 0.000 description 4
- 101100348848 Mus musculus Notch4 gene Proteins 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 238000011529 RT qPCR Methods 0.000 description 4
- 125000003342 alkenyl group Chemical group 0.000 description 4
- 125000000304 alkynyl group Chemical group 0.000 description 4
- 125000004429 atom Chemical group 0.000 description 4
- 230000000903 blocking effect Effects 0.000 description 4
- 239000006143 cell culture medium Substances 0.000 description 4
- 238000002648 combination therapy Methods 0.000 description 4
- 125000004122 cyclic group Chemical group 0.000 description 4
- 108010011222 cyclo(Arg-Pro) Proteins 0.000 description 4
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 4
- DLBFLQKQABVKGT-UHFFFAOYSA-L lucifer yellow dye Chemical compound [Li+].[Li+].[O-]S(=O)(=O)C1=CC(C(N(C(=O)NN)C2=O)=O)=C3C2=CC(S([O-])(=O)=O)=CC3=C1N DLBFLQKQABVKGT-UHFFFAOYSA-L 0.000 description 4
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 125000004076 pyridyl group Chemical group 0.000 description 4
- 125000006413 ring segment Chemical group 0.000 description 4
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- UGOMMVLRQDMAQQ-UHFFFAOYSA-N xphos Chemical group CC(C)C1=CC(C(C)C)=CC(C(C)C)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 UGOMMVLRQDMAQQ-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 206010012438 Dermatitis atopic Diseases 0.000 description 3
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 3
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-diisopropylethylamine Substances CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 3
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 3
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 3
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 201000008937 atopic dermatitis Diseases 0.000 description 3
- 125000002837 carbocyclic group Chemical group 0.000 description 3
- 238000000423 cell based assay Methods 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 125000000753 cycloalkyl group Chemical group 0.000 description 3
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 3
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000000069 prophylactic effect Effects 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 239000002356 single layer Substances 0.000 description 3
- 239000012312 sodium hydride Substances 0.000 description 3
- 229910000104 sodium hydride Inorganic materials 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 229910021642 ultra pure water Inorganic materials 0.000 description 3
- 239000012498 ultrapure water Substances 0.000 description 3
- OJVAMHKKJGICOG-UHFFFAOYSA-N 2,5-hexanedione Chemical compound CC(=O)CCC(C)=O OJVAMHKKJGICOG-UHFFFAOYSA-N 0.000 description 2
- SGUAFYQXFOLMHL-UHFFFAOYSA-N 2-hydroxy-5-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl}benzamide Chemical compound C=1C=C(O)C(C(N)=O)=CC=1C(O)CNC(C)CCC1=CC=CC=C1 SGUAFYQXFOLMHL-UHFFFAOYSA-N 0.000 description 2
- 102000004506 Blood Proteins Human genes 0.000 description 2
- 108010017384 Blood Proteins Proteins 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 102000002791 Interleukin-8B Receptors Human genes 0.000 description 2
- 108010018951 Interleukin-8B Receptors Proteins 0.000 description 2
- 230000004163 JAK-STAT signaling pathway Effects 0.000 description 2
- 229940123628 Lysine (K)-specific demethylase 1A inhibitor Drugs 0.000 description 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- 229940079156 Proteasome inhibitor Drugs 0.000 description 2
- 102000001253 Protein Kinase Human genes 0.000 description 2
- 108010090804 Streptavidin Proteins 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 238000011374 additional therapy Methods 0.000 description 2
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 2
- 229960004538 alprazolam Drugs 0.000 description 2
- 238000011319 anticancer therapy Methods 0.000 description 2
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 2
- 239000012148 binding buffer Substances 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 239000013592 cell lysate Substances 0.000 description 2
- 238000012054 celltiter-glo Methods 0.000 description 2
- QTMDXZNDVAMKGV-UHFFFAOYSA-L copper(ii) bromide Chemical compound [Cu+2].[Br-].[Br-] QTMDXZNDVAMKGV-UHFFFAOYSA-L 0.000 description 2
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 125000001162 cycloheptenyl group Chemical group C1(=CCCCCC1)* 0.000 description 2
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 206010052015 cytokine release syndrome Diseases 0.000 description 2
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 2
- 229960001259 diclofenac Drugs 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000012149 elution buffer Substances 0.000 description 2
- 230000004907 flux Effects 0.000 description 2
- 238000007429 general method Methods 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 125000002346 iodo group Chemical group I* 0.000 description 2
- 238000000021 kinase assay Methods 0.000 description 2
- 229960001632 labetalol Drugs 0.000 description 2
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 201000005962 mycosis fungoides Diseases 0.000 description 2
- 125000001624 naphthyl group Chemical group 0.000 description 2
- 229910052763 palladium Inorganic materials 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- SIOXPEMLGUPBBT-UHFFFAOYSA-N picolinic acid Chemical compound OC(=O)C1=CC=CC=N1 SIOXPEMLGUPBBT-UHFFFAOYSA-N 0.000 description 2
- 125000003367 polycyclic group Chemical group 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 2
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 2
- 239000003207 proteasome inhibitor Substances 0.000 description 2
- 108060006633 protein kinase Proteins 0.000 description 2
- 125000003226 pyrazolyl group Chemical group 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 125000005494 pyridonyl group Chemical group 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 2
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 2
- 238000010257 thawing Methods 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 1
- GBBSAMQTQCPOBF-UHFFFAOYSA-N 2,4,6-trimethyl-1,3,5,2,4,6-trioxatriborinane Chemical compound CB1OB(C)OB(C)O1 GBBSAMQTQCPOBF-UHFFFAOYSA-N 0.000 description 1
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 1
- JUIKUQOUMZUFQT-UHFFFAOYSA-N 2-bromoacetamide Chemical compound NC(=O)CBr JUIKUQOUMZUFQT-UHFFFAOYSA-N 0.000 description 1
- YKHQFTANTNMYPP-UHFFFAOYSA-N 2-bromopyridin-3-ol Chemical compound OC1=CC=CN=C1Br YKHQFTANTNMYPP-UHFFFAOYSA-N 0.000 description 1
- FGSAQRJRWCZLOB-UHFFFAOYSA-N 2-chloro-4-fluoropyridine Chemical compound FC1=CC=NC(Cl)=C1 FGSAQRJRWCZLOB-UHFFFAOYSA-N 0.000 description 1
- LIEPVGBDUYKPLC-UHFFFAOYSA-N 2-chloro-4-nitropyridine Chemical compound [O-][N+](=O)C1=CC=NC(Cl)=C1 LIEPVGBDUYKPLC-UHFFFAOYSA-N 0.000 description 1
- VTNULXUEOJMRKZ-UHFFFAOYSA-N 3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-(2H-tetrazol-5-ylmethyl)benzamide Chemical compound N=1NN=NC=1CNC(C1=CC(=CC=C1)OC1=NC(=CC(=C1)CN)C(F)(F)F)=O VTNULXUEOJMRKZ-UHFFFAOYSA-N 0.000 description 1
- MZSAMHOCTRNOIZ-UHFFFAOYSA-N 3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-phenylaniline Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(NC2=CC=CC=C2)C=CC=1 MZSAMHOCTRNOIZ-UHFFFAOYSA-N 0.000 description 1
- BAQKUNMKVAPWGU-UHFFFAOYSA-N 4-bromopyridin-2-amine Chemical compound NC1=CC(Br)=CC=N1 BAQKUNMKVAPWGU-UHFFFAOYSA-N 0.000 description 1
- 125000002471 4H-quinolizinyl group Chemical group C=1(C=CCN2C=CC=CC12)* 0.000 description 1
- 125000001054 5 membered carbocyclic group Chemical group 0.000 description 1
- KAHHAPNRIQLSFT-UHFFFAOYSA-N 5-methoxypyrimidin-2-amine Chemical compound COC1=CN=C(N)N=C1 KAHHAPNRIQLSFT-UHFFFAOYSA-N 0.000 description 1
- HPACHQWGMDXVOS-MRVPVSSYSA-N 5-tert-butyl-1-[(3R)-oxolan-3-yl]pyrazol-3-amine Chemical compound CC(C)(C)C1=CC(N)=NN1[C@H]1COCC1 HPACHQWGMDXVOS-MRVPVSSYSA-N 0.000 description 1
- HPACHQWGMDXVOS-QMMMGPOBSA-N 5-tert-butyl-1-[(3S)-oxolan-3-yl]pyrazol-3-amine Chemical compound CC(C)(C)C1=CC(N)=NN1[C@@H]1COCC1 HPACHQWGMDXVOS-QMMMGPOBSA-N 0.000 description 1
- ZHBXGHWSVIBUCQ-UHFFFAOYSA-N 5-tert-butyl-1h-pyrazol-3-amine Chemical compound CC(C)(C)C1=CC(N)=NN1 ZHBXGHWSVIBUCQ-UHFFFAOYSA-N 0.000 description 1
- 125000004008 6 membered carbocyclic group Chemical group 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- 206010000871 Acute monocytic leukaemia Diseases 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 208000003950 B-cell lymphoma Diseases 0.000 description 1
- 239000012664 BCL-2-inhibitor Substances 0.000 description 1
- 108091012583 BCL2 Proteins 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 229940123711 Bcl2 inhibitor Drugs 0.000 description 1
- 208000011691 Burkitt lymphomas Diseases 0.000 description 1
- 208000025721 COVID-19 Diseases 0.000 description 1
- 102100029968 Calreticulin Human genes 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- 229910021590 Copper(II) bromide Inorganic materials 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 102100026662 Delta and Notch-like epidermal growth factor-related receptor Human genes 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 208000016937 Extranodal nasal NK/T cell lymphoma Diseases 0.000 description 1
- 102000003964 Histone deacetylase Human genes 0.000 description 1
- 108090000353 Histone deacetylase Proteins 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000793651 Homo sapiens Calreticulin Proteins 0.000 description 1
- 101100443625 Homo sapiens DNER gene Proteins 0.000 description 1
- 101000997835 Homo sapiens Tyrosine-protein kinase JAK1 Proteins 0.000 description 1
- 101000934996 Homo sapiens Tyrosine-protein kinase JAK3 Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- 229940122245 Janus kinase inhibitor Drugs 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000035489 Monocytic Acute Leukemia Diseases 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- KQKBMHGOHXOHTD-KKUQBAQOSA-N N-[(2S)-5-[[(1R,2S)-2-(4-fluorophenyl)cyclopropyl]amino]-1-(4-methylpiperazin-1-yl)-1-oxopentan-2-yl]-4-(triazol-1-yl)benzamide Chemical compound FC1=CC=C(C=C1)[C@H]1[C@@H](C1)NCCC[C@@H](C(=O)N1CCN(CC1)C)NC(C1=CC=C(C=C1)N1N=NC=C1)=O KQKBMHGOHXOHTD-KKUQBAQOSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 229940122907 Phosphatase inhibitor Drugs 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 241000219061 Rheum Species 0.000 description 1
- 208000029052 T-cell acute lymphoblastic leukemia Diseases 0.000 description 1
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 102100033438 Tyrosine-protein kinase JAK1 Human genes 0.000 description 1
- 102100025387 Tyrosine-protein kinase JAK3 Human genes 0.000 description 1
- SAHIZENKTPRYSN-UHFFFAOYSA-N [2-[3-(phenoxymethyl)phenoxy]-6-(trifluoromethyl)pyridin-4-yl]methanamine Chemical compound O(C1=CC=CC=C1)CC=1C=C(OC2=NC(=CC(=C2)CN)C(F)(F)F)C=CC=1 SAHIZENKTPRYSN-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- BIVUUOPIAYRCAP-UHFFFAOYSA-N aminoazanium;chloride Chemical compound Cl.NN BIVUUOPIAYRCAP-UHFFFAOYSA-N 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 230000000181 anti-adherent effect Effects 0.000 description 1
- 239000003911 antiadherent Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000002047 benzodioxolyl group Chemical group O1OC(C2=C1C=CC=C2)* 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000005874 benzothiadiazolyl group Chemical group 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 125000000649 benzylidene group Chemical group [H]C(=[*])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 238000010256 biochemical assay Methods 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 229960001467 bortezomib Drugs 0.000 description 1
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 229910052729 chemical element Inorganic materials 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- GBRBMTNGQBKBQE-UHFFFAOYSA-L copper;diiodide Chemical compound I[Cu]I GBRBMTNGQBKBQE-UHFFFAOYSA-L 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000013058 crude material Substances 0.000 description 1
- 125000000392 cycloalkenyl group Chemical group 0.000 description 1
- 125000000522 cyclooctenyl group Chemical group C1(=CCCCCCC1)* 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 238000002784 cytotoxicity assay Methods 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 125000004856 decahydroquinolinyl group Chemical group N1(CCCC2CCCCC12)* 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 125000002576 diazepinyl group Chemical group N1N=C(C=CC=C1)* 0.000 description 1
- LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 description 1
- 229960005156 digoxin Drugs 0.000 description 1
- LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 description 1
- 229940043279 diisopropylamine Drugs 0.000 description 1
- 125000000532 dioxanyl group Chemical group 0.000 description 1
- 125000005879 dioxolanyl group Chemical group 0.000 description 1
- MKRTXPORKIRPDG-UHFFFAOYSA-N diphenylphosphoryl azide Chemical compound C=1C=CC=CC=1P(=O)(N=[N+]=[N-])C1=CC=CC=C1 MKRTXPORKIRPDG-UHFFFAOYSA-N 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- HKSZLNNOFSGOKW-UHFFFAOYSA-N ent-staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(C)O1 HKSZLNNOFSGOKW-UHFFFAOYSA-N 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 1
- VICYTAYPKBLQFB-UHFFFAOYSA-N ethyl 3-bromo-2-oxopropanoate Chemical compound CCOC(=O)C(=O)CBr VICYTAYPKBLQFB-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- BDTDECDAHYOJRO-UHFFFAOYSA-N ethyl n-(sulfanylidenemethylidene)carbamate Chemical compound CCOC(=O)N=C=S BDTDECDAHYOJRO-UHFFFAOYSA-N 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004475 heteroaralkyl group Chemical group 0.000 description 1
- 125000006038 hexenyl group Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000005980 hexynyl group Chemical group 0.000 description 1
- 239000003276 histone deacetylase inhibitor Substances 0.000 description 1
- 230000006951 hyperphosphorylation Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- UTCSSFWDNNEEBH-UHFFFAOYSA-N imidazo[1,2-a]pyridine Chemical compound C1=CC=CC2=NC=CN21 UTCSSFWDNNEEBH-UHFFFAOYSA-N 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 1
- 229960004801 imipramine Drugs 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 125000004594 isoindolinyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 229960004125 ketoconazole Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 229950002915 mivebresib Drugs 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- RDONXGFGWSSFMY-UHFFFAOYSA-N n-[4-(2,4-difluorophenoxy)-3-(6-methyl-7-oxo-1h-pyrrolo[2,3-c]pyridin-4-yl)phenyl]ethanesulfonamide Chemical compound C=1N(C)C(=O)C=2NC=CC=2C=1C1=CC(NS(=O)(=O)CC)=CC=C1OC1=CC=C(F)C=C1F RDONXGFGWSSFMY-UHFFFAOYSA-N 0.000 description 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 150000002829 nitrogen Chemical class 0.000 description 1
- 102000037979 non-receptor tyrosine kinases Human genes 0.000 description 1
- 108091008046 non-receptor tyrosine kinases Proteins 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 125000002868 norbornyl group Chemical group C12(CCC(CC1)C2)* 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 125000000160 oxazolidinyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 125000003566 oxetanyl group Chemical group 0.000 description 1
- 238000002638 palliative care Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 125000005981 pentynyl group Chemical group 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 125000001791 phenazinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3N=C12)* 0.000 description 1
- 125000001484 phenothiazinyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 description 1
- 125000001644 phenoxazinyl group Chemical group C1(=CC=CC=2OC3=CC=CC=C3NC12)* 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 229940081066 picolinic acid Drugs 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 229960003712 propranolol Drugs 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000004943 pyrimidin-6-yl group Chemical group N1=CN=CC=C1* 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229910052701 rubidium Inorganic materials 0.000 description 1
- 238000003375 selectivity assay Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 238000007921 solubility assay Methods 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- HKSZLNNOFSGOKW-FYTWVXJKSA-N staurosporine Chemical compound C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1[C@H]1C[C@@H](NC)[C@@H](OC)[C@]4(C)O1 HKSZLNNOFSGOKW-FYTWVXJKSA-N 0.000 description 1
- CGPUWJWCVCFERF-UHFFFAOYSA-N staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(OC)O1 CGPUWJWCVCFERF-UHFFFAOYSA-N 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- IOGXOCVLYRDXLW-UHFFFAOYSA-N tert-butyl nitrite Chemical compound CC(C)(C)ON=O IOGXOCVLYRDXLW-UHFFFAOYSA-N 0.000 description 1
- 239000012414 tert-butyl nitrite Substances 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 description 1
- 125000005958 tetrahydrothienyl group Chemical group 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000005308 thiazepinyl group Chemical group S1N=C(C=CC=C1)* 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 229910000404 tripotassium phosphate Inorganic materials 0.000 description 1
- 235000019798 tripotassium phosphate Nutrition 0.000 description 1
- 239000003656 tris buffered saline Substances 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 230000005747 tumor angiogenesis Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 229960001183 venetoclax Drugs 0.000 description 1
- LQBVNQSMGBZMKD-UHFFFAOYSA-N venetoclax Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=C3C=CNC3=NC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NCC1CCOCC1 LQBVNQSMGBZMKD-UHFFFAOYSA-N 0.000 description 1
- 229960001722 verapamil Drugs 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- WAEXFXRVDQXREF-UHFFFAOYSA-N vorinostat Chemical compound ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1 WAEXFXRVDQXREF-UHFFFAOYSA-N 0.000 description 1
- 229960000237 vorinostat Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Definitions
- Janus kinase 2 is a non-receptor tyrosine kinase involved in the JAK-STAT signaling pathway, which plays a role in cell processes such as immunity, cell division, and cell death.
- Dysfunction of the JAK-STAT pathway is implicated in various diseases, including cancer and other proliferative diseases, as well as diseases of the immune system.
- essentially all BCR-ABL1 -negative myeloproliferative neoplasms are associated with mutations that activate JAK2.
- JAK2 ⁇ i 6 ⁇ 7F is the most prevalent mutation in myeloproliferative neoplasms, occurring in approx.
- Inhibitors of JAKs are classified based on their binding mode. All currently approved JAK inhibitors are Type I inhibitors, which are those that bind the ATP- binding site in the active conformation of the kinase domain, thereby blocking catalysis (Vainchenker, W. et al.). However, increased phosphorylation of the JAK2 activation loop is observed with Type I inhibitors and may lead to acquired resistance in certain patients (Meyer S. C., Levine, R. L. Clin. Cancer Res. 2014, 20(8):2051-9).
- Type II inhibitors bind the ATP -binding site of the kinase domain in the inactive conformation and, therefore, may avoid hyperphosphorylation observed with Type I inhibitors (Wu, S. C. et al. Cancer Cell 2015 Jul 13, 28(1):29-41).
- the present disclosure provides compounds useful for inhibiting JAK2.
- provided compounds are useful for, among other things, treating and/or preventing diseases, disorders, or conditions associated with JAK2.
- the present disclosure provides a compound of Formula 1-1 or 1-2:
- Ring A, Ring B, L, V, W, X, Y, Z, R a , R x , and R y are as defined herein.
- structures depicted herein are meant to include all stereoisomeric (e.g., enantiomeric or diastereomeric) forms of the structure, as well as all geometric or conformational isomeric forms of the structure.
- the R and S configurations of each stereocenter are contemplated as part of the disclosure. Therefore, single stereochemical isomers, as well as enantiomeric, diastereomic, and geometric (or conformational) mixtures of provided compounds are within the scope of the disclosure.
- Table 1 shows one or more stereoisomers of a compound, and unless otherwise indicated, represents each stereoisomer alone and/or as a mixture. Unless otherwise stated, all tautomeric forms of provided compounds are within the scope of the disclosure.
- structures depicted herein are meant to include compounds that differ only in the presence of one or more isotopically enriched atoms.
- compounds having the present structures including replacement of hydrogen by deuterium or tritium, or replacement of a carbon by 13 C- or 14 C-enriched carbon, are within the scope of this disclosure.
- Aliphatic refers to a straight-chain (i.e., unbranched) or branched, optionally substituted hydrocarbon chain that is completely saturated or that contains one or more units of unsaturation, or a monocyclic or bicyclic hydrocarbon that is completely saturated or that contains one or more units of unsaturation but which is not aromatic (also referred to herein as “carbocyclic” or “cycloaliphatic”), that has a single point of attachment to the rest of the molecule.
- aliphatic groups contain 1-12 aliphatic carbon atoms. In some embodiments, aliphatic groups contain 1-6 aliphatic carbon atoms (e.g., Ci- 6 ).
- aliphatic groups contain 1-5 aliphatic carbon atoms (e.g., C1-5). In other embodiments, aliphatic groups contain 1-4 aliphatic carbon atoms (e.g., C1-4). In still other embodiments, aliphatic groups contain 1-3 aliphatic carbon atoms (e.g., C1-3), and in yet other embodiments, aliphatic groups contain 1-2 aliphatic carbon atoms (e.g., C1-2). Suitable aliphatic groups include, but are not limited to, linear or branched, substituted or unsubstituted alkyl, alkenyl, and alkynyl groups and hybrids thereof.
- aliphatic refers to a straight-chain (i.e., unbranched) or branched, optionally substituted hydrocarbon chain that is completely saturated or that contains one or more units of unsaturation that has a single point of attachment to the rest of the molecule.
- Alkyl refers to a saturated, optionally substituted straight or branched hydrocarbon group having (unless otherwise specified) 1-12, 1-10, 1-8, 1-6, 1-4, 1-3, or 1-2 carbon atoms (e.g., Ci-12, Ci-10, Ci-8, Ci- 6 , Ci-4, Ci- 3, or C1-2).
- exemplary alkyl groups include methyl, ethyl, propyl, butyl, pentyl, hexyl, and heptyl.
- Carbocyclyl The terms “carbocyclyl,” “carbocycle,” and “carbocyclic ring” as used herein, refer to saturated or partially unsaturated cyclic aliphatic monocyclic, bicyclic, or polycyclic ring systems, as described herein, having from 3 to 14 members, wherein the aliphatic ring system is optionally substituted as described herein.
- Carbocyclic groups include, without limitation, cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cycloheptyl, cycloheptenyl, cyclooctyl, cyclooctenyl, norbornyl, adamantyl, and cyclooctadienyl.
- “carbocyclyl” refers to an optionally substituted monocyclic C3-C8 hydrocarbon, or an optionally substituted C7-C10 bicyclic hydrocarbon that is completely saturated or that contains one or more units of unsaturation, but which is not aromatic, that has a single point of attachment to the rest of the molecule.
- the term “cycloalkyl” refers to an optionally substituted saturated ring system of about 3 to about 10 ring carbon atoms. In some embodiments, cycloalkyl groups have 3-6 carbons.
- Exemplary monocyclic cycloalkyl rings include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and cycloheptyl.
- cycloalkenyl refers to an optionally substituted non-aromatic monocyclic or multicyclic ring system containing at least one carbon-carbon double bond and having about 3 to about 10 carbon atoms.
- Exemplary monocyclic cycloalkenyl rings include cyclopentenyl, cyclohexenyl, and cycloheptenyl.
- Alkenyl refers to an optionally substituted straight or branched hydrocarbon chain having at least one double bond and having (unless otherwise specified) 2-12, 2-10, 2-8, 2-6, 2-4, or 2-3 carbon atoms (e.g., C2-12, C2-10, C2-8, C2-6, C2-4, or C2-3).
- alkenyl groups include ethenyl, propenyl, butenyl, pentenyl, hexenyl, and heptenyl.
- Alkynyl refers to an optionally substituted straight or branched chain hydrocarbon group having at least one triple bond and having (unless otherwise specified) 2-12, 2-10, 2-8, 2-6, 2-4, or 2-3 carbon atoms (e.g., C2-12, C2-10, C2-8, C2-6, C2-4, or C2-3).
- exemplary alkynyl groups include ethynyl, propynyl, butynyl, pentynyl, hexynyl, and heptynyl.
- Aryl refers to monocyclic and bicyclic ring systems having a total of six to fourteen ring members (e.g., C6-14), wherein at least one ring in the system is aromatic and wherein each ring in the system contains three to seven ring members.
- the term “aryl” may be used interchangeably with the term “aryl ring”.
- “aryl” refers to an aromatic ring system which includes, but not limited to, phenyl, naphthyl, anthracyl and the like, which may bear one or more substituents. Unless otherwise specified, “aryl” groups are hydrocarbons.
- Heteroaryl refers to monocyclic or bicyclic ring groups having 5 to 10 ring atoms (e.g., 5- to 6-membered monocyclic heteroaryl or 9- to 10-membered bicyclic heteroaryl); having 6, 10, or 14 p electrons shared in a cyclic array; and having, in addition to carbon atoms, from one to five heteroatoms.
- heteroaryl groups include, without limitation, thienyl, furanyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, oxazolyl, isoxazolyl, oxadiazolyl, thiazolyl, isothiazolyl, thiadiazolyl, pyridyl, pyridonyl, pyridazinyl, pyrimidinyl, pyrazinyl, indolizinyl, purinyl, naphthyridinyl, pteridinyl, imidazo[l,2- ajpyrimidinyl, imidazo[l,2-a]pyridinyl, thienopyrimidinyl, triazolopyridinyl, and benzoisoxazolyl.
- heteroaryl and “heteroar-”, as used herein, also include groups in which a heteroaromatic ring is fused to one or more aryl, cycloaliphatic, or heterocyclyl rings, where the radical or point of attachment is on the heteroaromatic ring (i.e., a bicyclic heteroaryl ring having 1 to 3 heteroatoms).
- Nonlimiting examples include indolyl, isoindolyl, benzothienyl, benzofuranyl, dibenzofuranyl, indazolyl, benzimidazolyl, benzothiazolyl, benzothiadiazolyl, benzoxazolyl, quinolyl, isoquinolyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl, 4 H quinolizinyl, carbazolyl, acridinyl, phenazinyl, phenothiazinyl, phenoxazinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, pyrido[2,3-b]-l,4-oxazin-3(4H)-one, and benzoisoxazolyl.
- heteroaryl may be used interchangeably with the terms “heteroaryl ring”, “heteroxazin
- Heteroatom refers to nitrogen, oxygen, or sulfur, and includes any oxidized form of nitrogen or sulfur, and any quatemized form of a basic nitrogen.
- Heterocycle As used herein, the terms “heterocycle”, “heterocyclyl”, and “heterocyclic ring” are used interchangeably and refer to a stable 3- to 8-membered monocyclic or 7- to 10-membered bicyclic heterocyclic moiety that is either saturated or partially unsaturated, and having, in addition to carbon atoms, one or more, such as one to four, heteroatoms, as defined above.
- nitrogen includes a substituted nitrogen.
- the nitrogen may be N (as in 3,4-dihydro-2H-pyrrolyl), NH (as in pyrrolidinyl), or NR + (as in N-substituted pyrrolidinyl).
- a heterocyclic ring can be attached to its pendant group at any heteroatom or carbon atom that results in a stable structure and any of the ring atoms can be optionally substituted.
- saturated or partially unsaturated heterocyclic radicals include, without limitation, tetrahydrofuranyl, tetrahydrothienyl, piperidinyl, decahydroquinolinyl, oxazolidinyl, piperazinyl, dioxanyl, dioxolanyl, diazepinyl, oxazepinyl, thiazepinyl, morpholinyl, and thiamorpholinyl.
- a heterocyclyl group may be mono-, bi-, tri-, or polycyclic, preferably mono-, bi-, or tricyclic, more preferably mono- or bicyclic.
- a bicyclic heterocyclic ring also includes groups in which the heterocyclic ring is fused to one or more aryl, heteroaryl, or cycloaliphatic rings.
- Exemplary bicyclic heterocyclic groups include indolinyl, isoindolinyl, benzodioxolyl, 1,3- dihydroisobenzofuranyl, 2,3-dihydrobenzofuranyl, and tetrahydroquinolinyl.
- a bicyclic heterocyclic ring can also be a spirocyclic ring system (e.g., 7- to 11-membered spirocyclic fused heterocyclic ring having, in addition to carbon atoms, one or more heteroatoms as defined above (e.g., one, two, three or four heteroatoms)).
- a spirocyclic ring system e.g., 7- to 11-membered spirocyclic fused heterocyclic ring having, in addition to carbon atoms, one or more heteroatoms as defined above (e.g., one, two, three or four heteroatoms)).
- Partially Unsaturated when referring to a ring moiety, means a ring moiety that includes at least one double or triple bond between ring atoms.
- the term “partially unsaturated” is intended to encompass rings having multiple sites of unsaturation, but is not intended to include aromatic (e.g., aryl or heteroaryl) moieties, as herein defined.
- Patient or subject refers to any organism to which a provided composition is or may be administered, e.g., for experimental, diagnostic, prophylactic, cosmetic, and/or therapeutic purposes. Typical patients or subjects include animals (e.g., mammals such as mice, rats, rabbits, non-human primates, and/or humans). In some embodiments, a patient is a human. In some embodiments, a patient or a subject is suffering from or susceptible to one or more disorders or conditions. In some embodiments, a patient or subject displays one or more symptoms of a disorder or condition. In some embodiments, a patient or subject has been diagnosed with one or more disorders or conditions. In some embodiments, a patient or a subject is receiving or has received certain therapy to diagnose and/or to treat a disease, disorder, or condition.
- animals e.g., mammals such as mice, rats, rabbits, non-human primates, and/or humans.
- a patient is a human.
- a patient or a subject is suffering from or susceptible to one or more disorders or conditions
- Substituted or optionally substituted As described herein, compounds of this disclosure may contain “optionally substituted” moieties.
- the term “substituted,” whether preceded by the term “optionally” or not, means that one or more hydrogens of the designated moiety are replaced with a suitable substituent. “Substituted” applies to one or more hydrogens that are either explicit or implicit from the structure (e.g., refers to at least . , p y g p y substituent at each substitutable position of the group, and when more than one position in any given structure may be substituted with more than one substituent selected from a specified group, the substituent may be either the same or different at every position.
- Combinations of substituents envisioned by this invention are preferably those that result in the formation of stable or chemically feasible compounds.
- stable refers to compounds that are not substantially altered when subjected to conditions to allow for their production, detection, and, in certain embodiments, their recovery, purification, and use for one or more of the purposes provided herein.
- Groups described as being “substituted” preferably have between 1 and 4 substituents, more preferably 1 or 2 substituents.
- Groups described as being “optionally substituted” may be unsubstituted or be “substituted” as described above.
- Suitable monovalent substituents on R° are independently halogen, -(CH 2 )O-2R ⁇ , -(haloR*), -(CH 2 )o-20H, -(CH 2 )O-20R ⁇ , -(CH 2 )O-
- Suitable divalent substituents that are bound to vicinal substitutable carbons of an “optionally substituted” group include: -0(CR * 2 ) 2-3 0-, wherein each independent occurrence of R * is selected from hydrogen, Ci- 6 aliphatic which may be substituted as defined below, or an unsubstituted 5-6-membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
- Suitable substituents on the aliphatic group of R * include halogen, - R*, -(haloR*), -OH, -OR*, -O(haloR'), -CN, -C(0)OH, -C(0)OR*, -NH 2 , -NHR*, -NR* 2, or -N0 2 , wherein each R* is unsubstituted or where preceded by “halo” is substituted only with one or more halogens, and is independently Ci-4 aliphatic, -CHzPh, -0(CH 2 )o-iPh, or a 3- to 6- membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
- Suitable substituents on a substitutable nitrogen of an “optionally substituted” group include -R ⁇ , -NR ⁇ 2 , -C(0)R ⁇ , -C(0)OR ⁇ , -C(0)C(0)R ⁇ ,
- each R ⁇ is independently hydrogen, Ci- 6 aliphatic which may be substituted as defined below, or an unsubstituted 3- to 6-membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or, notwithstanding the definition above, two independent occurrences of R ⁇ , taken together with their intervening atom(s) form an unsubstituted 3- to 12-membered saturated, partially unsaturated, or aryl mono- or bicyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
- Suitable substituents on the aliphatic group of R ⁇ are independently halogen, - R ⁇ , -(haloR*), -OH, -OR*, -O(haloR'), -CN, -C(0)OH, -C(0)OR*, -NH 2 , -NHR*, -NR* 2, or -N0 2 , wherein each R* is unsubstituted or where preceded by “halo” is substituted only with one or more halogens, and is independently Ci ⁇ i aliphatic, -CH 2 Ph, -0(CH 2 )o-iPh, or a 3- to 6- membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
- treat refers to any administration of a therapy that partially or completely alleviates, ameliorates, relieves, inhibits, delays onset of, reduces severity of, and/or reduces incidence of one or more symptoms, features, and/or causes of a particular disease, disorder, and/or condition.
- treatment may be of a subject who does not exhibit signs of the relevant disease, disorder and/or condition and/or of a subject who exhibits only early signs of the disease, disorder, and/or condition.
- such treatment may be of a subject who exhibits one or more established signs of the relevant disease, disorder and/or condition.
- treatment may be of a subject who has been diagnosed as suffering from the relevant disease, disorder, and/or condition.
- dashed bonds are each independently a single or double bond, as valency permits, such that the bicyclic ring system comprising V, X, Y, and W is aromatic;
- V is CR V or N
- W is CR W or N
- X is C or N
- Y is C or N; wherein at least one of V, W, X, and Y is N;
- Z is -O- or -NR Z -;
- R v , R w , R x , and R y are each independently hydrogen, halogen, -OR 1 , -N(R 1 )2, -SR 1 , optionally substituted Ci- 6 aliphatic, or-CN;
- R z is hydrogen or optionally substituted Ci- 6 aliphatic; each R 1 is independently hydrogen or optionally substituted Ci- 6 aliphatic;
- Ring A is optionally substituted phenyl, optionally substituted 5- to 6-membered monocyclic heteroaryl having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, optionally substituted 8- to 10-membered bicyclic heteroaryl having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, optionally substituted 3- to 7- membered saturated or partially unsaturated monocyclic carbocyclyl, optionally substituted 3- to 7-membered saturated or partially unsaturated monocyclic heterocyclyl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or optionally substituted 7- to 10-membered saturated or partially unsaturated bicyclic heterocyclyl having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur;
- Ring B is optionally substituted phenyl, optionally substituted 9- to 16-membered bicyclic or tricyclic aryl, optionally substituted 5- to 6-membered monocyclic heteroaryl having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, optionally substituted 8- to 10-membered bicyclic heteroaryl having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, optionally substituted 10- to 16-membered polycyclic heteroaryl having 1-5 heteroatoms independently selected from nitrogen, oxygen, and sulfur, optionally substituted 3- to 7-membered saturated or partially unsaturated monocyclic carbocyclyl, optionally substituted 7- to 16-membered saturated or partially unsaturated bicyclic or tricyclic carbocyclyl, optionally substituted 3- to 7-membered saturated or partially unsaturated monocyclic heterocyclyl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, optionally substituted 7- to 10-membered bicyclic heterocyclyl having 1-4 heteroatoms
- L is a covalent bond or a bivalent C1-3 straight or branched hydrocarbon chain; and R a is hydrogen, halogen, optionally substituted Ci- 6 aliphatic, optionally substituted phenyl, optionally substituted 5- to 6-membered monocyclic heteroaryl having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, optionally substituted 3- to 7- membered saturated or partially unsaturated monocyclic carbocyclyl, optionally substituted 3- to 7-membered saturated or partially unsaturated monocyclic heterocyclyl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or optionally substituted 7- to 10- membered saturated or partially unsaturated bicyclic heterocyclyl having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.
- the present disclosure provides a compound of Formula 1-1 : or a pharmaceutically acceptable salt thereof, wherein Ring A, Ring B, L, V, W, X, Y, Z, R a , R x , and R y are as defined above for Formula 1-1 and described in classes and subclasses herein, both singly and in combination.
- the present disclosure provides a compound of Formula 1-2: or a pharmaceutically acceptable salt thereof, wherein Ring A, Ring B, L, V, W, X, Y, Z, R a , R x , and R y are as defined above for Formula 1-2 and described in classes and subclasses herein, both singly and in combination.
- the present disclosure provides a compound of Formula IA: or a pharmaceutically acceptable salt thereof, wherein Ring A, Ring B, L, Z, R a , R v , R x , and R y are as defined above for Formula 1-1 and described in classes and subclasses herein, both singly and in combination.
- the present disclosure provides a compound of Formula IB:
- Ring A, Ring B, L, Z, R a , R w , R x , and R y are as defined above for Formula 1-1 and described in classes and subclasses herein, both singly and in combination.
- the present disclosure provides a compound of Formula IC:
- Ring A, Ring B, L, Z, R a , R w , R x , and R y are as defined above for Formula 1-2 and described in classes and subclasses herein, both singly and in combination.
- the present disclosure provides a compound of Formula ID:
- Ring A, Ring B, L, Z, R a , R v , R w , R x , and R y are as defined above for Formula 1-1 and described in classes and subclasses herein, both singly and in combination.
- the present disclosure provides a compound of Formula IE:
- Ring A, Ring B, L, Z, R a , R v , R w , R x , and R y are as defined above for Formula 1-1 and described in classes and subclasses herein, both singly and in combination.
- the present disclosure provides a compound of Formula II-l :
- R x , and R y are as defined above for Formula 1-1 and described in classes and subclasses herein, both singly and in combination; and:
- R b is hydrogen, halogen, -CN, -OR, -SR, -N(R) 2 , -NO2, -C(0)R ⁇ -C(0)OR, -C(0)N(R) 2 , - OC(0)R ⁇ -OC(0)N(R) 2 , -OC(0)OR, -OSO2R, -0S0 2 N(R) 2 , -N(R)C(0)R ⁇ -N(R)S0 2 R ⁇ - SOzR’, -S0 2 N(R) 2 , -SChR’, optionally substituted Ci- 6 aliphatic, optionally substituted 3- to 6-membered saturated or partially unsaturated monocyclic carbocyclyl, optionally substituted 3- to 6-membered saturated or partially unsaturated monocyclic heterocyclyl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or optionally substituted 5- to 6-membered monocyclic heteroaryl having 1-4 heteroatoms independently selected from nitrogen, oxygen
- the present disclosure provides a compound of Formula II-2:
- Ring A, Ring B, L, V, W, X, Y, Z, R a , R b , R x , and R y are as defined above for Formula 1-2 and described in classes and subclasses herein, both singly and in combination; and:
- R b is hydrogen, halogen, -CN, -OR, -SR, -N(R) 2 , -NO2, -C(0)R ⁇ -C(0)0R, -C(0)N(R) 2 , - 0C(0)R ⁇ -0C(0)N(R) 2 , -0C(0)0R, -0S0 2 R, -0S0 2 N(R) 2 , -N(R)C(0)R ⁇ -N(R)S0 2 R ⁇ - SOzR’, -S0 2 N(R) 2 , -SCbR’, optionally substituted Ci- 6 aliphatic, optionally substituted 3- to 6-membered saturated or partially unsaturated monocyclic carbocyclyl, optionally substituted 3- to 6-membered saturated or partially unsaturated monocyclic heterocyclyl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or optionally substituted 5- to 6-membered monocyclic heteroaryl having 1-4 heteroatoms
- the present disclosure provides a compound of Formula III- 1 :
- Ring A, L, V, W, X, Y, Z, R a , R x , and R y are as defined above for Formula 1-1 and described in classes and subclasses herein, both singly and in combination; and:
- R 2 is -N(R)2, -N(R)C(0)R ⁇ -C(0)N(R)2, or -N(R)C(0)N(R) 2 ; each R is independently hydrogen, optionally substituted Ci- 6 aliphatic, optionally substituted 3- to 7-membered saturated or partially unsaturated carbocyclyl, or optionally substituted 3- to 7-membered saturated or partially unsaturated monocyclic heterocyclyl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or two R when attached to the same nitrogen atom are taken together form an optionally substituted 3- to 7- membered saturated or partially unsaturated monocyclic heterocyclyl having 0-2 additional heteroatoms independently selected from nitrogen, oxygen, and sulfur; and each R’ is independently optionally substituted Ci- 6 aliphatic or optionally substituted 3- to 7- membered saturated or partially unsaturated carbocyclyl.
- the present disclosure provides a compound of Formula III-2:
- Ring A, L, V, W, X, Y, Z, R a , R x , and R y are as defined above for Formula 1-2 and described in classes and subclasses herein, both singly and in combination; and:
- R 2 is -N(R)2, -N(R)C(0)R ⁇ -C(0)N(R)2, or -N(R)C(0)N(R) 2 ; each R is independently hydrogen, optionally substituted Ci- 6 aliphatic, optionally substituted 3- to 7-membered saturated or partially unsaturated carbocyclyl, or optionally substituted 3- to 7-membered saturated or partially unsaturated monocyclic heterocyclyl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or two R when attached to the same nitrogen atom are taken together form an optionally substituted 3- to 7- membered saturated or partially unsaturated monocyclic heterocyclyl having 0-2 additional heteroatoms independently selected from nitrogen, oxygen, and sulfur; and each R’ is independently optionally substituted Ci- 6 aliphatic or optionally substituted 3- to 7- membered saturated or partially unsaturated carbocyclyl.
- the present disclosure provides a compound of Formula IV- 1 :
- Ring A, L, V, W, X, Y, Z, R a , R x , and R y are as defined above for Formula 1-1 and described in classes and subclasses herein, both singly and in combination; and:
- Ring B1 is an optionally substituted ring selected from phenyl, 5- to 6-membered monocyclic heteroaryl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, 5- to 6-membered saturated or partially unsaturated monocyclic carbocyclyl, and 5- to 6- membered saturated or partially unsaturated monocyclic heterocyclyl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein Ring B 1 is fused to Ring B2;
- Ring B2 is an optionally substituted ring selected from phenyl, 5- to 6-membered monocyclic heteroaryl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, 5- to 6-membered saturated or partially unsaturated monocyclic carbocyclyl, and 5- to 6- membered saturated or partially unsaturated monocyclic heterocyclyl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein Ring B2 is optionally (i) further fused to Ring B3, or (ii) Ring B2 and Ring B3 combine to form a spirocycle; and
- Ring B3 when present, is an optionally substituted ring selected from phenyl, 5- to 6-membered monocyclic heteroaryl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, 3- to 7-membered saturated or partially unsaturated monocyclic carbocyclyl, and 3- to 7-membered saturated or partially unsaturated monocyclic heterocyclyl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur.
- the present disclosure provides a compound of Formula IV-2:
- Ring A, L, V, W, X, Y, Z, R a , R x , and R y are as defined above for Formula 1-2 and described in classes and subclasses herein, both singly and in combination; and:
- Ring B1 is an optionally substituted ring selected from phenyl, 5- to 6-membered monocyclic heteroaryl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, 5- to 6-membered saturated or partially unsaturated monocyclic carbocyclyl, and 5- to 6- membered saturated or partially unsaturated monocyclic heterocyclyl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein Ring B 1 is fused to Ring B2;
- Ring B2 is an optionally substituted ring selected from phenyl, 5- to 6-membered monocyclic heteroaryl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, 5- to 6-membered saturated or partially unsaturated monocyclic carbocyclyl, and 5- to 6- membered saturated or partially unsaturated monocyclic heterocyclyl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein Ring B2 is optionally (i) further fused to Ring B3, or (ii) Ring B2 and Ring B3 combine to form a spirocycle; and Ring B3, when present, is an optionally substituted ring selected from phenyl, 5- to 6-membered monocyclic heteroaryl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, 3- to 7-membered saturated or partially unsaturated monocyclic carbocyclyl, and 3- to 7-membered saturated or partially unsaturated monocyclic heterocyclyl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur.
- V is CR V . In some embodiments, V is N.
- W is CR W . In some embodiments, W is N.
- X is C. In some embodiments, X is N.
- Y is C. In some embodiments, Y is N.
- one and only one of V, W, X, and Y is N.
- two of V, W, X, and Y are N.
- no more than two of V, W, X, and Y are N.
- three of V, W, X, and Y are N.
- no more than three of V, W, X, and Y are N.
- Z is -0-. In some embodiments, Z is -NR Z -. In some embodiments, Z is - NH-.
- R v is hydrogen, halogen, or optionally substituted Ci-6 aliphatic.
- R v is hydrogen.
- R v is halogen.
- R v is fluoro.
- R v is chloro.
- R v is -OR 1 .
- R v is -OR 1 , wherein R 1 is optionally substituted Ci-6 aliphatic.
- R v is -N ⁇ R 1 ⁇ .
- R v is -SR 1 .
- R v is - SR 1 , wherein R 1 is optionally substituted Ci-6 aliphatic.
- R v is optionally substituted Ci-6 aliphatic. In some embodiments, R v is optionally substituted straight-chain or branched Ci-6 aliphatic (i.e., optionally substituted acyclic Ci-6 aliphatic). In some embodiments, R v is optionally substituted Ci-6 alkyl. In some embodiments, R v is optionally substituted Ci-4 alkyl. In some embodiments, R v is optionally substituted C1-2 alkyl. In some embodiments, R v is optionally substituted methyl (e.g., methyl optionally substituted with one or more fluoro). In some embodiments, R v is -CN.
- R w is hydrogen, halogen, or optionally substituted Ci-6 aliphatic.
- R w is hydrogen.
- R w is halogen.
- R w is fluoro.
- R w is chloro.
- R w is -OR 1 .
- R w is -OR 1 , wherein R 1 is optionally substituted Ci-6 aliphatic.
- R w is -N ⁇ R 1 ⁇ .
- R w is -SR 1 . In some embodiments, R w is -SR 1 , wherein R 1 is optionally substituted Ci-6 aliphatic. In some embodiments, R w is optionally substituted Ci-6 aliphatic. In some embodiments, R w is optionally substituted straight-chain or branched Ci-6 aliphatic (i.e., optionally substituted acyclic Ci-6 aliphatic). In some embodiments, R w is optionally substituted Ci-6 alkyl. In some embodiments, R w is optionally substituted Ci-4 alkyl. In some embodiments, R w is optionally substituted C1-2 alkyl. In some embodiments, R w is optionally substituted methyl (e.g., methyl optionally substituted with one or more fluoro). In some embodiments, R w is -CN.
- R x is hydrogen, halogen, or optionally substituted Ci-6 aliphatic. In some embodiments, R x is hydrogen or optionally substituted Ci- 6 aliphatic. In some embodiments, R x is hydrogen or Ci- 6 alkyl. In some embodiments, R x is hydrogen. In some embodiments, R x is halogen. In some embodiments, R x is fluoro. In some embodiments, R x is chloro. In some embodiments, R x is -OR 1 .
- R x is -OR 1 , wherein R 1 is optionally substituted Ci- 6 aliphatic. In some embodiments, R x is In some embodiments, R x is - SR 1 . In some embodiments, R x is -SR 1 , wherein R 1 is optionally substituted Ci- 6 aliphatic. In some embodiments, R x is optionally substituted Ci- 6 aliphatic. In some embodiments, R x is optionally substituted straight-chain or branched Ci- 6 aliphatic (i.e., optionally substituted acyclic Ci- 6 aliphatic). In some embodiments, R x is optionally substituted Ci- 6 alkyl.
- R x is optionally substituted Ci-4 alkyl. In some embodiments, R x is optionally substituted C1-2 alkyl. In some embodiments, R x is optionally substituted methyl (e.g., methyl optionally substituted with one or more fluoro). In some embodiments, R x is -CN.
- R y is hydrogen, halogen, or optionally substituted Ci- 6 aliphatic.
- R y is hydrogen.
- R y is halogen.
- R y is fluoro.
- R y is chloro.
- R y is -OR 1 .
- R y is -OR 1 , wherein R 1 is optionally substituted Ci- 6 aliphatic.
- V is N, Y is CR y , and R y is -OR 1 wherein R 1 is optionally substituted Ci- 6 aliphatic.
- R y is -N(R X )2.
- R y is -SR 1 .
- R y is -SR 1 , wherein R 1 is optionally substituted Ci- 6 aliphatic.
- V is N, Y is CR y , and R y is -SR 1 wherein R 1 is optionally substituted Ci- 6 aliphatic.
- R y is optionally substituted Ci- 6 aliphatic.
- R y is optionally substituted straight-chain or branched Ci- 6 aliphatic (i.e., optionally substituted acyclic Ci- 6 aliphatic). In some embodiments, R y is optionally substituted Ci- 6 alkyl. In some embodiments, R y is optionally substituted Ci-4 alkyl. In some embodiments, R y is optionally substituted C1-2 alkyl. In some embodiments, R y is optionally substituted methyl (e.g., methyl optionally substituted with one or more fluoro). In some embodiments, R y is -CN.
- R z is hydrogen.
- R z is optionally substituted Ci- 6 aliphatic.
- R z is optionally substituted straight-chain or branched Ci- 6 aliphatic (i.e., optionally substituted acyclic Ci- 6 aliphatic).
- R z is optionally substituted Ci- 6 alkyl.
- R z is optionally substituted Ci-4 alkyl.
- R z is unsubstituted Ci-4 alkyl.
- R z is optionally substituted C1-2 alkyl. In some embodiments, R z is unsubstituted C1-2 alkyl.
- each R 1 is independently hydrogen or optionally substituted Ci-4 aliphatic. In some embodiments, each R 1 is independently hydrogen or optionally substituted C1-2 aliphatic. In some embodiments, each R 1 is hydrogen. In some embodiments, each R 1 is independently optionally substituted Ci- 6 aliphatic. In some embodiments, each R 1 is independently optionally substituted straight-chain or branched Ci- 6 aliphatic (i.e., optionally substituted acyclic Ci- 6 aliphatic).
- each R 1 is independently optionally substituted Ci-4 aliphatic. In some embodiments, each R 1 is independently optionally substituted straight-chain or branched Ci-4 aliphatic (i.e., optionally substituted acyclic Ci-4 aliphatic). In some embodiments, each R 1 is independently optionally substituted C1-2 aliphatic. In some embodiments, each R 1 is independently hydrogen or Ci- 6 alkyl. In some embodiments, each R 1 is independently hydrogen or Ci-4 alkyl. In some embodiments, each R 1 is independently hydrogen or C1-2 alkyl.
- Ring A is (i) optionally substituted on a substitutable carbon atom with one or more groups independently selected from oxo, halogen, R°, -CN, -OR°, -SR°, -N(R°)2, -NO2, -C(0)R°, -C(0)OR°, -C(0)NR°2, -OC(0)R°, -0C(0)NR° 2 , -OC(0)OR°, -0S(0) 2 R°, - 0S(0) 2 NR°2, -N(R°)C(0)R°, -N(R 0 )S(0) 2 R°, -S(0) 2 R°, -S0 2 NR°2, and -S(0) 2 OR°, and (ii) optionally substituted on a substitutable nitrogen atom with one
- Ring A is (i) optionally substituted on a substitutable carbon atom with one or more groups independently selected from oxo, halogen, and R°, and (ii) optionally substituted on a substitutable nitrogen atom with one or more groups selected from -R ⁇ . In some embodiments, Ring A is (i) optionally substituted on a substitutable carbon atom with one or more groups independently selected from halogen and R°, and (ii) optionally substituted on a substitutable nitrogen atom with one or more groups selected from -R ⁇ .
- Ring A is (i) optionally substituted on a substitutable carbon atom with one or more groups independently selected from R°, and (ii) optionally substituted on a substitutable nitrogen atom with one or more groups selected from - R ⁇ .
- Ring A is optionally substituted with one or more R b (i.e., in addition to being substituted with -L-R a ), wherein R b is as defined in Formula II-l above and described in classes and subclasses herein.
- Ring A is substituted with zero, one, two, three, four, or five R b , as valency allows.
- Ring A is optionally substituted 5- to 6-membered monocyclic heteroaryl having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, optionally substituted 8- to 10-membered bicyclic heteroaryl having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, optionally substituted 3- to 7- membered saturated or partially unsaturated monocyclic carbocyclyl, optionally substituted 3- to 7-membered saturated or partially unsaturated monocyclic heterocyclyl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or optionally substituted 7- to 10- membered saturated or partially unsaturated bicyclic heterocyclyl having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.
- Ring A is optionally substituted 5- to 6-membered monocyclic heteroaryl having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, optionally substituted 8- to 10-membered bicyclic heteroaryl having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, optionally substituted 3- to 7- membered saturated or partially unsaturated monocyclic heterocyclyl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or optionally substituted 7- to 10- membered saturated or partially unsaturated bicyclic heterocyclyl having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.
- Ring A is optionally substituted phenyl.
- Ring A is optionally substituted 5- to 6-membered monocyclic heteroaryl having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, Ring A is optionally substituted 5- to 6-membered monocyclic heteroaryl having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, Ring A is optionally substituted 5-membered monocyclic heteroaryl having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, Ring A is optionally substituted 5-membered monocyclic heteroaryl having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, Ring A is optionally substituted pyrazolyl.
- Ring A is optionally substituted 6- membered monocyclic heteroaryl having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, Ring A is optionally substituted 6-membered monocyclic heteroaryl having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, Ring A is optionally substituted pyridonyl.
- Ring A is optionally substituted 8- to 10-membered bicyclic heteroaryl having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, Ring A is optionally substituted 8-membered bicyclic heteroaryl having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, Ring A is optionally substituted 9-membered bicyclic heteroaryl having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, Ring A is optionally substituted tetrahydropyrazolo[l,5-a]pyridinyl. In some embodiments, Ring A is optionally substituted 10-membered bicyclic heteroaryl having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.
- Ring A is optionally substituted 3- to 7-membered saturated or partially unsaturated monocyclic carbocyclyl. In some embodiments, Ring A is optionally substituted C3-7 cycloalkyl. In some embodiments, Ring A is optionally substituted 3-membered saturated or partially unsaturated monocyclic carbocyclyl. In some embodiments, Ring A is optionally substituted 4-membered saturated or partially unsaturated monocyclic carbocyclyl. In some embodiments, Ring A is optionally substituted 5-membered saturated or partially unsaturated monocyclic carbocyclyl. In some embodiments, Ring A is optionally substituted 6- membered saturated or partially unsaturated monocyclic carbocyclyl. In some embodiments, Ring A is optionally substituted 7-membered saturated or partially unsaturated monocyclic carbocyclyl.
- Ring A is optionally substituted 3- to 7-membered saturated or partially unsaturated monocyclic heterocyclyl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, Ring A is optionally substituted 3- membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, Ring A is optionally substituted 4-membered saturated or partially unsaturated monocyclic heterocyclyl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, Ring A is optionally substituted 5-membered saturated or partially unsaturated monocyclic heterocyclyl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur.
- Ring A is optionally substituted 6-membered saturated or partially unsaturated monocyclic heterocyclyl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, Ring A is optionally substituted 7- membered saturated or partially unsaturated monocyclic heterocyclyl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur.
- Ring A is optionally substituted 7- to 10-membered saturated or partially unsaturated bicyclic heterocyclyl having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, Ring A is optionally substituted 7- membered saturated or partially unsaturated bicyclic heterocyclyl having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, Ring A is optionally substituted 8-membered saturated or partially unsaturated bicyclic heterocyclyl having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, Ring A is optionally substituted 9-membered saturated or partially unsaturated bicyclic heterocyclyl having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, Ring A is optionally substituted 10-membered saturated or partially unsaturated bicyclic heterocyclyl having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.
- L is a covalent bond.
- L is a bivalent C1-3 straight or branched hydrocarbon chain.
- L is a bivalent C1-2 straight or branched hydrocarbon chain.
- L is methylene (i.e., -CH2-).
- L is -CH2CH2-.
- L is -CH2CH2CH2-.
- L is a covalent bond or -CH2-.
- R a is halogen, optionally substituted Ci- 6 aliphatic, optionally substituted phenyl, optionally substituted 5- to 6-membered monocyclic heteroaryl having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, optionally substituted 3- to 7- membered saturated or partially unsaturated monocyclic carbocyclyl, optionally substituted 3- to 7-membered saturated or partially unsaturated monocyclic heterocyclyl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or optionally substituted 7- to 10- membered saturated or partially unsaturated bicyclic heterocyclyl having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.
- R a is optionally substituted Ci- 6 aliphatic or optionally substituted 3- to 7-membered saturated or partially unsaturated monocyclic heterocyclyl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, R a is optionally substituted Ci- 6 alkyl or optionally substituted 3- to 6-membered saturated monocyclic heterocyclyl having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur.
- R a is hydrogen. In some embodiments, R a is not hydrogen. [0068] In some embodiments, R a is halogen. In some embodiments, R a is fluoro, chloro, bromo, or iodo. In some embodiments, R a is fluoro. In some embodiments, R a is chloro.
- R a is optionally substituted Ci- 6 aliphatic. In some embodiments, R a is optionally substituted straight-chain or branched Ci- 6 aliphatic (i.e., optionally substituted acyclic Ci- 6 aliphatic). In some embodiments, R a is optionally substituted Ci- 6 alkyl. In some embodiments, R a is optionally substituted Ci-4 alkyl. In some embodiments, R a is -CHS.
- R a is optionally substituted phenyl.
- R a is optionally substituted 5- to 6-membered monocyclic heteroaryl having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur. [0072] In some embodiments, R a is optionally substituted 3- to 7-membered saturated or partially unsaturated monocyclic carbocyclyl.
- R a is optionally substituted 3- to 7-membered saturated or partially unsaturated monocyclic heterocyclyl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur.
- R a is optionally substituted 4- to 6- membered saturated monocyclic heterocyclyl having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur.
- R a is optionally substituted 3- membered saturated monocyclic heterocyclyl having 1 heteroatom independently selected from nitrogen, oxygen, and sulfur.
- R a is optionally substituted 4-membered saturated monocyclic heterocyclyl having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur.
- R a is oxetanyl. In some embodiments, R a is optionally substituted 5-membered saturated monocyclic heterocyclyl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, R a is tetrahydrofuranyl. In some embodiments, R a is optionally substituted 6-membered saturated monocyclic heterocyclyl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, R a is optionally substituted 7-membered saturated monocyclic heterocyclyl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur.
- R a is optionally substituted 7- to 10-membered saturated or partially unsaturated bicyclic heterocyclyl having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, R a is optionally substituted 7- to 10- membered saturated, spirocyclic, bicyclic heterocyclyl having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, R a is optionally substituted 7- to 8-membered saturated, spirocyclic, bicyclic heterocyclyl having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur.
- R a is selected from the group consisting of: ,
- ⁇ R a is -R a (i.e., L is a covalent bond).
- ⁇ is -CFh-R 3 (i.e., L is a Ci hydrocarbon chain).
- is -CH2CH2-R a i.e., L is a C2 straight hydrocarbon chain).
- R b up to five occurrences of R b may be present, as allowed by valency rules, and is each independently halogen, -CN, -OR, -SR, -N(R)2, -NO2, -C(0)R’, -C(0)OR, - C(0)N(R)2, -0C(0)R ⁇ -0C(0)N(R)2, -OC(0)OR, -OSO2R, -0S0 2 N(R) 2 , -N(R)C(0)R’, - N(R)S02R’, -SCkR’, -S0 2 N(R) 2 , -SCbR’, optionally substituted Ci- 6 aliphatic, optionally substituted 3- to 6-membered saturated or partially unsaturated monocyclic carbocycly
- each occurrence of R b is independently optionally substituted Ci-6 aliphatic or optionally substituted 3- to 6-membered saturated or partially unsaturated monocyclic carbocyclyl. In some embodiments, each occurrence of R b is independently optionally substituted Ci-4 alkyl or optionally substituted C3-C4 cycloalkyl. In some embodiments, each occurrence of R b is independently C3-4 cycloalkyl or Ci-4 alkyl optionally substituted with one or more halogen. In some embodiments, each occurrence of R b is independently Ci-4 alkyl or C3-C4 cycloalkyl.
- R b is hydrogen
- R b is halogen. In some embodiments, R b is fluoro, chloro, bromo, or iodo. In some embodiments, R b is fluoro. In some embodiments, R b is chloro.
- R b is optionally substituted Ci-6 aliphatic. In some embodiments, R b is optionally substituted straight-chain or branched Ci-6 aliphatic (i.e., optionally substituted acyclic Ci-6 aliphatic). In some embodiments, R b is optionally substituted Ci-6 alkyl. In some embodiments, R b is optionally substituted Ci-4 alkyl. In some embodiments, R b is Ci-4 alkyl optionally substituted with one or more of halogen. In some embodiments, R b is Ci-4 alkyl. In some embodiments, R b is -CH3 or -C(CH3)3.
- R b is optionally substituted 3- to 6-membered saturated or partially unsaturated monocyclic carbocyclyl. In some embodiments, R b is optionally substituted C3-C6 cycloalkyl. In some embodiments, R b is optionally substituted 3-membered saturated or partially unsaturated monocyclic carbocyclyl. In some embodiments, R b is cyclopropyl. In some embodiments, R b is optionally substituted 4-membered saturated or partially unsaturated monocyclic carbocyclyl. In some embodiments, R b is optionally substituted 5-membered saturated or partially unsaturated monocyclic carbocyclyl.
- R b is optionally substituted 6-membered saturated or partially unsaturated monocyclic carbocyclyl. [0083] In some embodiments, R b is optionally substituted 3- to 6-membered saturated or partially unsaturated monocyclic heterocyclyl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur.
- R b is optionally substituted 5- to 6-membered monocyclic heteroaryl having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, R b is optionally substituted 5- to 6-membered monocyclic heteroaryl having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur.
- IP-2, IV- 1, and IV-2 optionally substituted In some embodiments, optionally substituted is optionally substituted In some embodiments, optionally substituted is optionally substituted In some embodiments, optionally substituted is optionally substituted In some embodiments, optionally substituted is optionally substituted
- Ring B (including Ring B1 and/or Ring B2 and/or, when present, Ring B3) is (i) optionally substituted on a substitutable carbon atom with one or more groups independently selected from oxo, halogen, R°, -CN, -OR°, -SR°, -N(R°)2, -NCte, -C(0)R°, - C(0)0R°, -C(0)NR°2, -0C(0)R°, -0C(0)NR°2, -0C(0)0R°, -0S(0) 2 R°, -0S(0) 2 NR°2, - N(R°)C(0)R°, -N(R°)C(0)NR°2, -N(R 0 )S(0) 2 R°, -S(0) 2 R°, -S(0) 2 R°,
- Ring B is (i) optionally substituted on a substitutable carbon atom with one or more groups independently selected from oxo, halogen, R°, -CN, -OR°, -N(R°)2, -C(0)NR°2, -N(R°)C(0)R°, and - N(R°)C(0)NR°2, and (ii) optionally substituted on a substitutable nitrogen with -R ⁇ .
- Ring B is optionally substituted on a substitutable carbon atom with one or more groups independently selected from -N(R°)2, -C(0)NR°2, -N(R°)C(0)R°, and -N(R°)C(0)NR°2.
- Ring B is optionally substituted phenyl, optionally substituted 5- to 6-membered monocyclic heteroaryl having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, optionally substituted 3- to 7-membered saturated or partially unsaturated monocyclic carbocyclyl, or optionally substituted 3- to 7-membered saturated or partially unsaturated monocyclic heterocyclyl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur.
- Ring B is optionally substituted 9- to 16-membered bicyclic or tricyclic aryl, optionally substituted 8- to 10-membered bicyclic heteroaryl having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, optionally substituted 10- to 16-membered polycyclic heteroaryl having 1-5 heteroatoms independently selected from nitrogen, oxygen, and sulfur, optionally substituted 7- to 16- membered saturated or partially unsaturated bicyclic or tricyclic carbocyclyl, optionally substituted 7- to 10-membered bicyclic heterocyclyl having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or optionally substituted 10- to 16-membered polycyclic heterocyclyl having 1-5 heteroatoms independently selected from nitrogen, oxygen, and sulfur.
- Ring B is optionally substituted 5- to 6-membered monocyclic heteroaryl having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, optionally substituted 8- to 10-membered bicyclic heteroaryl having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, optionally substituted 10- to 16- membered polycyclic heteroaryl having 1-5 heteroatoms independently selected from nitrogen, oxygen, and sulfur, optionally substituted 3- to 7-membered saturated or partially unsaturated monocyclic heterocyclyl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, optionally substituted 7- to 10-membered bicyclic heterocyclyl having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or optionally substituted 10- to 16-membered polycyclic heterocyclyl having 1-5 heteroatoms independently selected from nitrogen, oxygen, and sulfur.
- Ring B is optionally substituted 5- to 6-membered monocyclic heteroaryl having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur or optionally substituted 3- to 7-membered saturated or partially unsaturated monocyclic heterocyclyl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur.
- Ring B is optionally substituted 8- to 10- membered bicyclic heteroaryl having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, optionally substituted 10- to 16-membered polycyclic heteroaryl having 1-5 heteroatoms independently selected from nitrogen, oxygen, and sulfur, optionally substituted 7- to 10-membered bicyclic heterocyclyl having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or optionally substituted 10- to 16-membered polycyclic heterocyclyl having 1-5 heteroatoms independently selected from nitrogen, oxygen, and sulfur.
- Ring B is optionally substituted 8- to 10-membered bicyclic heteroaryl having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur or optionally substituted 10- to 16-membered polycyclic heteroaryl having 1-5 heteroatoms independently selected from nitrogen, oxygen, and sulfur.
- Ring B is monocyclic. In some embodiments, Ring B is polycyclic (e.g., bicyclic or tricyclic). In some embodiments, Ring B is bicyclic. In some embodiments, each ring in a bicyclic ring system of Ring B contains at least one heteroatom. In some embodiments, one and only one ring of a bicyclic ring system of Ring B contains no heteroatoms. In some embodiments, each ring in a bicyclic ring system of Ring B is aromatic. In some embodiments, one and only one ring of a bicyclic ring system of Ring B is aromatic. In some embodiments, no ring in a bicyclic ring system of Ring B is aromatic.
- Ring B is optionally substituted phenyl.
- Ring B is optionally substituted 9- to 16-membered bicyclic or tricyclic aryl. In some embodiments, Ring B is optionally substituted 9- to 10-membered bicyclic aryl. In some embodiments, Ring B is optionally substituted 9-membered bicyclic aryl (e.g., a 5-membered carbocycle fused to a phenyl ring). In some embodiments, Ring B is optionally substituted 10-membered bicyclic aryl (e.g., naphthyl or a 6-membered carbocycle fused to a phenyl ring).
- Ring B is optionally substituted 5- to 6-membered monocyclic heteroaryl having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, Ring B is optionally substituted 5- to 6-membered monocyclic heteroaryl having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, Ring B is optionally substituted 5-membered monocyclic heteroaryl having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, Ring B is optionally substituted 5-membered monocyclic heteroaryl having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur.
- Ring B is optionally substituted 6-membered monocyclic heteroaryl having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, Ring B is optionally substituted 6-membered monocyclic heteroaryl having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, Ring B is optionally substituted pyridyl.
- Ring B is optionally substituted 8- to 10-membered bicyclic heteroaryl having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, Ring B is optionally substituted 8-membered bicyclic heteroaryl having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, Ring B is optionally substituted 9-membered bicyclic heteroaryl having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, Ring B is optionally substituted 10-membered bicyclic heteroaryl having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.
- Ring B is optionally substituted 10- to 16-membered polycyclic heteroaryl having 1-5 heteroatoms independently selected from nitrogen, oxygen, and sulfur.
- Ring B is optionally substituted 3- to 7-membered saturated or partially unsaturated monocyclic carbocyclyl. In some embodiments, Ring B is optionally substituted C3-7 cycloalkyl. In some embodiments, Ring B is optionally substituted 3-membered saturated or partially unsaturated monocyclic carbocyclyl. In some embodiments, Ring B is optionally substituted 4-membered saturated or partially unsaturated monocyclic carbocyclyl. In some embodiments, Ring B is optionally substituted 5-membered saturated or partially unsaturated monocyclic carbocyclyl. In some embodiments, Ring B is optionally substituted 6- membered saturated or partially unsaturated monocyclic carbocyclyl. In some embodiments, Ring B is optionally substituted 7-membered saturated or partially unsaturated monocyclic carbocyclyl.
- Ring B is optionally substituted 7- to 16-membered saturated or partially unsaturated bicyclic or tricyclic carbocyclyl.
- Ring B is optionally substituted 3- to 7-membered saturated or partially unsaturated monocyclic heterocyclyl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, Ring B is optionally substituted 3- membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, Ring B is optionally substituted 4-membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, Ring B is optionally substituted 5-membered saturated or partially unsaturated monocyclic heterocyclyl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur.
- Ring B is optionally substituted 6-membered saturated or partially unsaturated monocyclic heterocyclyl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, Ring B is optionally substituted 7- membered saturated or partially unsaturated monocyclic heterocyclyl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur.
- Ring B is optionally substituted 7- to 10-membered bicyclic heterocyclyl having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, Ring B is optionally substituted 7- to 10-membered fused bicyclic heterocyclyl having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, Ring B is optionally substituted 7-membered bicyclic heterocyclyl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, Ring B is optionally substituted 8-membered bicyclic heterocyclyl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur.
- Ring B is optionally substituted 9-membered bicyclic heterocyclyl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, Ring B is optionally substituted 10-membered bicyclic heterocyclyl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur.
- Ring B is optionally substituted 10- to 16-membered polycyclic heterocyclyl having 1-5 heteroatoms independently selected from nitrogen, oxygen, and sulfur.
- Ring B is , wherein R 2 is as defined in Formula
- Ring B is
- R 2 is -N(R)C(0)R’ or -C(0)N(R) 2.
- R 2 is -N(R)C(0)R ⁇ In some embodiments, R 2 is - N(H)C(0)R ⁇ In some embodiments, R 2 is -N(R)C(0)(optionally substituted Ci- 6 aliphatic). In some embodiments, R 2 is -N(H)C(0)(optionally substituted Ci- 6 aliphatic). In some embodiments, R 2 is -N(R)C(0)(CI-6 aliphatic). In some embodiments, R 2 is -N(H)C(0)(CI-6 aliphatic). In some embodiments, R 2 is -N(R)C(0)(straight-chain or branched Ci- 6 aliphatic).
- R 2 is -N(H)C(0)(straight-chain or branched Ci- 6 aliphatic). In some embodiments, R 2 is -N(R)C(0)(optionally substituted Ci- 6 alkyl). In some embodiments, R 2 is - N(H)C(0)(optionally substituted Ci- 6 alkyl). In some embodiments, R 2 is -N(R)C(0)(CI-6 alkyl). In some embodiments, R 2 is -N(H)C(0)(CI-6 alkyl). In some embodiments, R 2 is - N(R)C(0)(optionally substituted Ci-4 alkyl). In some embodiments, R 2 is -N(H)C(0)(optionally substituted Ci-4 alkyl).
- R 2 is -N(R)C(0)(CI-4 alkyl). In some embodiments, R 2 is -N(H)C(0)(CI-4 alkyl). In some embodiments, R 2 is -N(R)C(0)(optionally substituted Ci- 2 alkyl). In some embodiments, R 2 is -N(H)C(0)(optionally substituted Ci- 2 alkyl). In some embodiments, R 2 is -N(R)C(0)(Ci- 2 alkyl). In some embodiments, R 2 is - N(H)C(0)(CI- 2 alkyl). In some embodiments, R 2 is -N(R)C(0)CH3. In some embodiments, R 2 is -N(H)C(0)CH3.
- R 2 is -N(R)C(0)(optionally substituted C3-7 carbocyclyl). In some embodiments, R 2 is -N(H)C(0)(optionally substituted C3-7 carbocyclyl). In some embodiments, R 2 is -N(R)C(0)(optionally substituted C3-7 cycloalkyl). In some embodiments, R 2 is -N(H)C(0)(optionally substituted C3-7 cycloalkyl). In some embodiments, R 2 is -N(R)C(0)(C 3 - 6 cycloalkyl). In some embodiments, R 2 is -N(H)C(0)(C 3 - 6 cycloalkyl). [0107] In some embodiments, R 2 is -C(0)N(R)2. In some embodiments, R 2 is -
- R 2 is -C(0)N(H)(CI- 6 aliphatic). In some embodiments, R 2 is -C(0)N(R)(straight-chain or branched Ci- 6 aliphatic). In some embodiments, R 2 is -C(0)N(H)(straight-chain or branched Ci- 6 aliphatic). In some embodiments, R 2 is -C(0)N(R)(CI- 6 alkyl). In some embodiments, R 2 is -C(0)N(H)(CI- 6 alkyl). In some embodiments, R 2 is -C(0)N(R)(CI-4 alkyl). In some embodiments, R 2 is -
- R 2 is -C(0)N(R)(CI-2 alkyl). In some embodiments, R 2 is -C(0)N(H)(CI-2 alkyl).
- R 2 is -N(R)2. In some embodiments, R 2 is -N(H)(R).
- R 2 is -N(R)C(0)N(R)2. In some embodiments, R 2 is -
- R 2 is -N(R)C(0)N(R)2, wherein the two R groups attached to the same nitrogen are taken together to form an optionally substituted 3- to 7-membered saturated or partially unsaturated monocyclic heterocyclyl having 0-2 additional heteroatoms independently selected from nitrogen, oxygen, and sulfur.
- R 2 is -N(R)C(0)N(R)2, wherein the two R groups attached to the same nitrogen are taken together to form an optionally substituted 3- to 5-membered saturated monocyclic heterocyclyl having 0-1 additional heteroatoms independently selected from nitrogen, oxygen, and sulfur.
- R 2 is -N(H)C(0)N(R)2.
- R 2 is -N(H)C(0)N(R)2, wherein the two R groups attached to the same nitrogen are taken together to form an optionally substituted 3- to 7-membered saturated or partially unsaturated monocyclic heterocyclyl having 0-2 additional heteroatoms independently selected from nitrogen, oxygen, and sulfur.
- R 2 is -N(H)C(0)N(R)2, wherein the two R groups attached to the same nitrogen are taken together to form an optionally substituted 3- to 5-membered saturated monocyclic heterocyclyl having 0-1 additional heteroatoms independently selected from nitrogen, oxygen, and sulfur.
- each R is independently hydrogen or optionally substituted Ci- 6 aliphatic.
- R is hydrogen.
- R is optionally substituted Ci- 6 aliphatic.
- R is optionally substituted straight-chain or branched Ci- 6 aliphatic (i.e., optionally substituted acyclic Ci- 6 aliphatic).
- R is optionally substituted Ci- 6 alkyl.
- R is optionally substituted 3- to 7- membered saturated or partially unsaturated carbocyclyl. In some embodiments, R is optionally substituted 3- to 7-membered saturated or partially unsaturated monocyclic heterocyclyl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, two R when attached to the same nitrogen atom are taken together form a 3- to 7- membered saturated or partially unsaturated monocyclic heterocyclyl having 0-2 additional heteroatoms independently selected from nitrogen, oxygen, and sulfur.
- R’ is optionally substituted Ci- 6 aliphatic.
- R’ is optionally substituted straight-chain or branched Ci- 6 aliphatic (i.e., optionally substituted acyclic Ci- 6 aliphatic).
- R’ is optionally substituted Ci- 6 alkyl.
- R’ is optionally substituted Ci-4 alkyl.
- R’ is unsubstituted Ci-4 alkyl.
- R’ is optionally substituted C1-2 alkyl.
- R’ is unsubstituted C1-2 alkyl. In some embodiments, R’ is methyl. In some embodiments, R’ is 3- to 7-membered saturated or partially unsaturated carbocyclyl. In some embodiments, R’ is optionally substituted C3-6 cycloalkyl.
- Ring B is , wherein Ring B1 and Ring B2 are defined as in Formula IV- 1 and described in classes and subclasses herein, both singly and in combination; and Ring B1 is fused to Ring B2; and Ring B2 is optionally (i) further fused to Ring B3 or (ii) Ring B2 and Ring B3 combine to form a spirocycle.
- Ring B1 is an optionally substituted ring selected from 5- to 6- membered monocyclic heteroaryl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur and 5- to 6-membered saturated or partially unsaturated monocyclic heterocyclyl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur.
- Ring B1 is optionally substituted phenyl. In some embodiments, when Ring B1 is phenyl, Ring B2 contains at least one heteroatom.
- Ring B1 is optionally substituted 5- to 6-membered monocyclic heteroaryl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, Ring B1 is unsubstituted 5- to 6-membered monocyclic heteroaryl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, Ring B1 is optionally substituted 5-membered monocyclic heteroaryl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, Ring B1 is optionally substituted 6-membered monocyclic heteroaryl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur.
- Ring B1 is optionally substituted 5- to 6-membered saturated or partially unsaturated monocyclic carbocyclyl. In some embodiments, when Ring B1 is optionally substituted 5- to 6-membered saturated or partially unsaturated monocyclic carbocyclyl, Ring B2 contains at least one heteroatom. In some embodiments, when Ring B2 is not aromatic, Ring B1 is optionally substituted 5- to 6-membered saturated monocyclic carbocyclyl. In some embodiments, Ring B1 is optionally substituted 5- to 6-membered partially saturated monocyclic carbocyclyl.
- Ring B1 is optionally substituted 5- to 6-membered saturated or partially unsaturated monocyclic heterocyclyl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur.
- Ring B2 when Ring B2 is not aromatic, Ring B1 is optionally substituted 5- to 6-membered saturated monocyclic heterocyclyl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur.
- Ring B1 is optionally substituted 5- to 6-membered partially saturated monocyclic heterocyclyl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur.
- Ring B2 is an optionally substituted ring selected from 5- to 6- membered monocyclic heteroaryl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur and 5- to 6-membered saturated or partially unsaturated monocyclic heterocyclyl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur.
- Ring B2 is optionally substituted phenyl. In some embodiments, when Ring B2 is phenyl, Ring B1 contains at least one heteroatom.
- Ring B2 is optionally substituted 5- to 6-membered monocyclic heteroaryl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, Ring B2 is optionally substituted 5-membered monocyclic heteroaryl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, Ring B2 is optionally substituted 6-membered monocyclic heteroaryl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur.
- Ring B2 is optionally substituted 5- to 6-membered saturated or partially unsaturated monocyclic carbocyclyl. In some embodiments, when Ring B2 is optionally substituted 5- to 6-membered saturated or partially unsaturated monocyclic carbocyclyl, Ring B1 contains at least one heteroatom. In some embodiments, when Ring B1 (and Ring B3, if present) is not aromatic, Ring B2 is optionally substituted 5- to 6-membered saturated monocyclic carbocyclyl. In some embodiments, Ring B2 is optionally substituted 5- to 6-membered partially saturated monocyclic carbocyclyl.
- Ring B2 is optionally substituted 5- to 6-membered saturated or partially unsaturated monocyclic heterocyclyl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur.
- Ring B1 when Ring B1 (and Ring B3, if present) is not aromatic, Ring B2 is optionally substituted 5- to 6-membered saturated monocyclic heterocyclyl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur.
- Ring B2 is optionally substituted 5- to 6-membered partially saturated monocyclic heterocyclyl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur.
- Ring B1 and Ring B2 are both optionally substituted 5- to 6- membered monocyclic heteroaryl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur.
- Ring B1 is optionally substituted 5-membered monocyclic heteroaryl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur
- Ring B2 is optionally substituted 6-membered monocyclic heteroaryl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur.
- Ring B1 is optionally substituted 6-membered monocyclic heteroaryl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur
- Ring B2 is optionally substituted 5-membered monocyclic heteroaryl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur.
- Ring B2 is further fused to Ring B3. In some embodiments, Ring B2 and Ring B3 combine to form a spirocycle.
- Ring B3, when present, is optionally substituted phenyl.
- Ring B3 is 5- to 6-membered monocyclic heteroaryl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur.
- Ring B3 is 3- to 7-membered saturated or partially unsaturated monocyclic carbocyclyl.
- Ring B3, when not fused to an aromatic Ring B2, is 3- to 7-membered saturated monocyclic carbocyclyl.
- Ring B3 is 3- to 7-membered partially saturated monocyclic carbocyclyl.
- Ring B3 is 3- to 7-membered saturated or partially unsaturated monocyclic heterocyclyl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, Ring B3, when not fused to an aromatic Ring B2, is 3- to 7-membered saturated monocyclic heterocyclyl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, Ring B3 is 3- to 7-membered partially saturated monocyclic heterocyclyl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur.
- the present disclosure provides compounds selected from Table 1:
- the present disclosure encompasses the recognition that provided compounds display certain desirable characteristics, e.g., as compared to other known compounds.
- provided compounds are more potent in one or more biochemical or cellular assays (e.g., the JAK2 Binding Assay or SET2-pSTAT5 Cellular Assay described herein) and/or have one or more other characteristics that make them more suitable for drug development, such as better selectivity over other kinases and/or better ADME (absorption, distribution, metabolism, and excretion) properties including but not limited to better permeability, cytotoxicity, hepatocyte stability, solubility, and/or plasma protein binding profiles (e.g., based on assays described in the ensuing examples), than other known compounds.
- provided compounds display certain desirable characteristics in one or more assays described herein, e.g., compared to other known compounds.
- provided compounds are provided and/or utilized in a salt form (e.g., a pharmaceutically acceptable salt form).
- a salt form e.g., a pharmaceutically acceptable salt form.
- Reference to a compound provided herein is understood to include reference to salts thereof, unless otherwise indicated.
- Pharmaceutically acceptable salt forms are known in the art. For example, S. M. Berge, et al. describes pharmaceutically acceptable salts in detail in J. Pharmaceutical Sciences, 66:1-19(1977).
- Provided compounds may generally be made by the processes described in the ensuing schemes and examples.
- provided compounds are prepared according to the following Scheme: wherein LG is a suitable leaving group (e.g., halogen, e.g., fluoro, chloro, or bromo) and Ring A, Ring B, L, V, W, X, Y, Z, R a , R x , and R y are as defined above for Formula 1-1 and described in classes and subclasses herein, both singly and in combination.
- LG is a suitable leaving group (e.g., halogen, e.g., fluoro, chloro, or bromo) and Ring A, Ring B, L, V, W, X, Y, Z, R a , R x , and R y are as defined above for Formula 1-1 and described in classes and subclasses herein, both singly and in combination.
- compound A-l is prepared by a process comprising contacting intermediate A.1-1 with intermediate A.2 in the presence of a suitable base (e.g., NaOtBu).
- compound A-l is prepared by a process comprising contacting intermediate A.1-1 with intermediate A.2 in the presence of a suitable base (e.g., NaOtBu), a suitable metal complex (e.g., a palladium complex such as tris(dibenzylideneacetone)dipalladium(0)), and optionally a suitable ligand (e.g., 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene).
- a suitable base e.g., NaOtBu
- a suitable metal complex e.g., a palladium complex such as tris(dibenzylideneacetone)dipalladium(0)
- a suitable ligand e.g., 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene
- provided compounds are prepared according to the following Scheme: wherein LG is a suitable leaving group (e.g., halogen, e.g., fluoro, chloro, or bromo) and Ring A, Ring B, L, V, W, X, Y, Z, R a , R x , and R y are as defined above for Formula 1-2 and described in classes and subclasses herein, both singly and in combination.
- LG is a suitable leaving group (e.g., halogen, e.g., fluoro, chloro, or bromo) and Ring A, Ring B, L, V, W, X, Y, Z, R a , R x , and R y are as defined above for Formula 1-2 and described in classes and subclasses herein, both singly and in combination.
- compound A-2 is prepared by a process comprising contacting intermediate A.1-2 with intermediate A.2 in the presence of a suitable base.
- compound A-2 is prepared by a process comprising
- provided compounds are prepared according to the following Scheme: wherein LG is a suitable leaving group (e.g., halogen, e.g., fluoro, chloro, or bromo) and Ring A, Ring B, L, V, W, X, Y, Z, R a , R x , and R y are as defined above for Formula 1-1 and described in classes and subclasses herein, both singly and in combination.
- LG is a suitable leaving group (e.g., halogen, e.g., fluoro, chloro, or bromo) and Ring A, Ring B, L, V, W, X, Y, Z, R a , R x , and R y are as defined above for Formula 1-1 and described in classes and subclasses herein, both singly and in combination.
- compound B-1 is prepared by a process comprising contacting intermediate B.1-1 with intermediate B.2 in the presence of a suitable base.
- provided compounds are prepared according to the following Scheme: wherein LG is a suitable leaving group (e.g., halogen, e.g., fluoro, chloro, or bromo) and Ring A, Ring B, L, V, W, X, Y, Z, R a , R x , and R y are as defined above for Formula 1-2 and described in classes and subclasses herein, both singly and in combination.
- LG is a suitable leaving group (e.g., halogen, e.g., fluoro, chloro, or bromo) and Ring A, Ring B, L, V, W, X, Y, Z, R a , R x , and R y are as defined above for Formula 1-2 and described in classes and subclasses herein, both singly and in combination.
- compound B-2 is prepared by a process comprising contacting intermediate B.1-2 with intermediate B.2 in the presence of a suitable base.
- provided compounds are prepared according to the following Scheme: wherein LG 1 is a suitable leaving group (e.g., halogen, e.g., fluoro, chloro, or bromo); LG 2 is a suitable leaving group (e.g., halogen, e.g., fluoro, chloro, or bromo); and Ring A, L, R, R’, V, W, X, Y, Z, R a , R x , and R y are as defined above for Formula 1-1 and described in classes and subclasses herein, both singly and in combination.
- LG 1 is a suitable leaving group
- LG 2 is a suitable leaving group
- Ring A, L, R, R’, V, W, X, Y, Z, R a , R x , and R y are as defined above for Formula 1-1 and described in classes and subclasses herein, both singly and in combination.
- intermediate C.3-1 is prepared by a process comprising contacting intermediate C.1-1 with intermediate C.2 in the presence of a suitable base (e.g., t-BuOK).
- compound C-l is prepared by a process comprising contacting intermediate C.3-1 with intermediate C.4 in the presence of a suitable base (e.g., CS2CO3).
- compound C-l is prepared by a process comprising contacting intermediate C.3-1 with intermediate C.4 in the presence of a suitable base (e.g., CS2CO3), a suitable metal complex (e.g., a palladium complex such as tris(dibenzylideneacetone)dipalladium(0)), and optionally a suitable ligand (e.g., 2-dicyclohexylphosphino-2',4',6'-triisopropylbiphenyl).
- a suitable base e.g., CS2CO3
- a suitable metal complex e.g., a palladium complex such as tris(dibenzylideneacetone)dipalladium(0)
- a suitable ligand e.g., 2-dicyclohexylphosphino-2',4',6'-triisopropylbiphenyl.
- provided compounds are prepared according to the following Scheme: wherein LG 1 is a suitable leaving group (e.g., halogen, e.g., fluoro, chloro, or bromo); LG 2 is a suitable leaving group (e.g., halogen, e.g., fluoro, chloro, or bromo); and Ring A, L, R, R’, V, W, X, Y, Z, R a , R x , and R y are as defined above for Formula 1-2 and described in classes and subclasses herein, both singly and in combination.
- LG 1 is a suitable leaving group (e.g., halogen, e.g., fluoro, chloro, or bromo)
- LG 2 is a suitable leaving group (e.g., halogen, e.g., fluoro, chloro, or bromo)
- intermediate C.3-2 is prepared by a process comprising contacting intermediate C.1-2 with intermediate C.2 in the presence of a suitable base.
- compound C-2 is prepared by a process comprising contacting intermediate C.3-2 with intermediate C.4 in the presence of a suitable base.
- compound C-2 is prepared by a process comprising contacting intermediate C.3-2 with intermediate C.4 in the presence of a suitable base, a suitable metal complex, and optionally a suitable ligand.
- provided compounds are prepared according to the following Scheme: wherein LG is a suitable leaving group (e.g., halogen, e.g., fluoro, chloro, or bromo) and Ring A, Ring B, L, V, W, X, Y, Z, R a , R x , and R y are as defined above for Formula 1-1 and described in classes and subclasses herein, both singly and in combination.
- compound D-1 is prepared by a process comprising contacting intermediate D.1-1 with intermediate D.2 in the presence of a suitable base.
- compound D-1 is prepared by a process comprising contacting intermediate D.1-1 with intermediate D.2 in the presence of a suitable base, a suitable metal complex, and optionally a suitable ligand.
- provided compounds are prepared according to the following Scheme: wherein LG is a suitable leaving group (e.g., halogen, e.g., fluoro, chloro, or bromo) and Ring A, Ring B, L, V, W, X, Y, Z, R a , R x , and R y are as defined above for Formula 1-2 and described in classes and subclasses herein, both singly and in combination.
- LG is a suitable leaving group (e.g., halogen, e.g., fluoro, chloro, or bromo) and Ring A, Ring B, L, V, W, X, Y, Z, R a , R x , and R y are as defined above for Formula 1-2 and described in classes and subclasses herein, both singly and in combination.
- compound D-2 is prepared by a process comprising contacting intermediate D.1-2 with intermediate D.2 in the presence of a suitable base.
- compound D-2 is prepared by a process comprising
- a provided compound is obtained by a process comprising a purification method described in the Examples section.
- a compound is the 1 st eluting isomer.
- a compound is the 2 nd eluting isomer.
- a compound is the 3 rd eluting isomer.
- a compound is the 4 th eluting isomer.
- a compound is the 5 th , 6 th , 7 th , 8 th , or more eluting isomer.
- compositions comprising a compound provided herein with one or more other components.
- provided compositions comprise and/or deliver a compound described herein (e.g., compounds of Formulae 1-1, 1-2, IA, IB, IC, ID, IE, II- 1, II-2, III- 1 , III-2, IV- 1, and IV-2).
- a provided composition is a pharmaceutical composition that comprises and/or delivers a compound provided herein (e.g., compounds of Formulae 1-1, 1-2, IA, IB, IC, ID, IE, II-l, II-2, III-l, III-2, IV- 1, and IV-2) and further comprises a pharmaceutically acceptable carrier.
- Pharmaceutical compositions typically contain an active agent (e.g., a compound described herein) in an amount effective to achieve a desired therapeutic effect while avoiding or minimizing adverse side effects.
- provided pharmaceutical compositions comprise a compound described herein and one or more fillers, disintegrants, lubricants, glidants, anti-adherents, and/or anti-statics, etc.
- compositions can be in a variety of forms including oral dosage forms, topical creams, topical patches, iontophoresis forms, suppository, nasal spray and/or inhaler, eye drops, intraocular injection forms, depot forms, as well as injectable and infusible solutions.
- Methods of preparing pharmaceutical compositions are well known in the art.
- provided compounds are formulated in a unit dosage form for ease of administration and uniformity of dosage.
- unit dosage form refers to a physically discrete unit of an active agent (e.g., a compound described herein) for administration to a subject. Typically, each such unit contains a predetermined quantity of active agent.
- a unit dosage form contains an entire single dose of the agent. In some embodiments, more than one unit dosage form is administered to achieve a total single dose. In some embodiments, administration of multiple unit dosage forms is required, or expected to be required, in order to achieve an intended effect.
- a unit dosage form may be, for example, a liquid pharmaceutical composition containing a predetermined quantity of one or more active agents, a solid pharmaceutical composition (e.g., a tablet, a capsule, or the like) containing a predetermined amount of one or more active agents, a sustained release formulation containing a predetermined quantity of one or more active agents, or a drug delivery device containing a predetermined amount of one or more active agents, etc.
- a liquid pharmaceutical composition containing a predetermined quantity of one or more active agents
- a solid pharmaceutical composition e.g., a tablet, a capsule, or the like
- sustained release formulation containing a predetermined quantity of one or more active agents
- a drug delivery device containing a predetermined amount of one or more active agents
- compositions may be administered using any amount and any route of administration effective for treating or lessening the severity of any disease or disorder described herein.
- provided compounds and compositions are useful in medicine (e.g., as therapy).
- provided compounds and compositions are useful in research as, for example, analytical tools and/or control compounds in biological assays.
- the present disclosure provides methods of administering provided compounds or compositions to a subject in need thereof. In some embodiments, the present disclosure provides methods of administering provided compounds or compositions to a subject suffering from or susceptible to a disease, disorder, or condition associated with JAK2. [0146] In some embodiments, provided compounds are useful as JAK2 inhibitors. In some embodiments, provided compounds are useful as Type II JAK2 inhibitors. In some embodiments, the present disclosure provides methods of inhibiting JAK2 in a subject comprising administering a provided compound or composition. In some embodiments, the present disclosure provides methods of inhibiting JAK2 in a biological sample comprising contacting the sample with a provided compound or composition.
- JAK e.g., JAK2
- JAK2 has been implicated in various diseases, disorders, and conditions, such as myeloproliferative neoplasms (Vainchenker, W. et al., FlOOOResearch 2018, 7(F1000 Faculty Rev):82), atopic dermatitis (Rodrigues, M. A. and Torres, T. J. Derm. Treat. 2019, 31(1), 33-40.) and acute respiratory syndrome, hyperinflammation, and/or cytokine storm syndrome ( The Lancet. doi:10.1016/S0140-6736(20)30628-0).
- the present disclosure provides methods of treating a disease, disorder or condition associated with JAK2 in a subject in need thereof comprising administering to the subject a provided compound or composition.
- a disease, disorder or condition is associated with overexpression of JAK2.
- the present disclosure provides methods of treating cancer, comprising administering a provided compound or composition to a subject in need thereof.
- the present disclosure provides methods of treating proliferative diseases, comprising administering a provided compound or composition to a subject in need thereof.
- the present disclosure provides methods of treating a hematological malignancy, comprising administering a provided compound or composition to a subject in need thereof.
- a hematological malignancy is leukemia (e.g., chronic lymphocytic leukemia, acute lymphoblastic leukemia, T-cell acute lymphoblastic leukemia, chronic myelogenous leukemia, acute myelogenous leukemia, or acute monocytic leukemia).
- a hematological malignancy is lymphoma (e.g., Burkitt’s lymphoma, Hodgkin’s lymphoma, or non-Hodgkin’s lymphoma).
- a non- Hodgkin’s lymphoma is a B-cell lymphoma.
- a non-Hodgkin’s lymphoma is a NK/T-cell lymphoma (e.g., cutaneous T-cell lymphoma).
- a hematological malignancy is myeloma (e.g., multiple myeloma).
- a hematological malignancy is myeloproliferative neoplasm (e.g., polycythemia vera, essential thrombocytopenia, or myelofibrosis).
- a hematological malignancy is myelodysplastic syndrome.
- the present disclosure provides methods of treating an inflammatory disease, disorder, or condition (e.g., acute respiratory syndrome, hyperinflammation, and/or cytokine storm syndrome (including those associated with COVID- 19) or atopic dermatitis), comprising administering a provided compound or composition to a subject in need thereof.
- an inflammatory disease, disorder, or condition e.g., acute respiratory syndrome, hyperinflammation, and/or cytokine storm syndrome (including those associated with COVID- 19) or atopic dermatitis
- a provided compound or composition is administered as part of a combination therapy.
- combination therapy refers to those situations in which a subject is simultaneously exposed to two or more therapeutic or prophylactic regimens (e.g., two or more therapeutic or prophylactic agents).
- the two or more regimens may be administered simultaneously; in some embodiments, such regimens may be administered sequentially (e.g., all “doses” of a first regimen are administered prior to administration of any doses of a second regimen); in some embodiments, such agents are administered in overlapping dosing regimens.
- “administration” of combination therapy may involve administration of one or more agent(s) or modality(ies) to a subject receiving the other agent(s) or modality(ies) in the combination.
- combination therapy does not require that individual agents be administered together in a single composition (or even necessarily at the same time), although in some embodiments, two or more agents, or active moieties thereof, may be administered together in a combination composition.
- a provided compound or composition is administered to a subject who is receiving or has received one or more additional therapies (e.g., an anti-cancer therapy and/or therapy to address one or more side effects of such anti-cancer therapy, or otherwise to provide palliative care).
- additional therapies include, but are not limited to, BCL2 inhibitors (e.g., venetoclax), HDAC inhibitors (e.g., vorinostat), BET inhibitors (e.g., mivebresib), proteasome inhibitors (e.g., bortezomib), LSD1 inhibitors (e.g., IMG-7289), and CXCR2 inhibitors.
- JAK2 inhibitors Useful combinations of a JAK2 inhibitor with BCL2, HDAC, BET, and proteasome inhibitors have been demonstrated in cells derived from cutaneous T-cell lymphoma patients (Yumeen, S., et al., Blood Adv. 2020, 4(10), 2213-2226).
- CXCR2 activity has been shown to modulate signaling pathways involved in tumor growth, angiogenesis, and/or metastasis, including the JAK-STAT3 pathway (Jaffer, T., Ma, D. Transl. Cancer Res. 2016, 5(Suppl. 4), S616-S628).
- Example 1 /V-(4-((2-((4,4-dimethyl-4,5,6,7-tetrahydropyrazolo[l,5-a]pyridin-2-yl)amino)- [l,2,4]triazolo[l,5-a]pyridin-7-yl)oxy)pyridin-2-yl)acetamide
- Compound 1.12 can also be used to prepare compound 1-5 using methods described herein.
- Example 2 A-(4-((2-((5-cyclopropyl- 1 -methyl-2-oxo- 1 ,2-dihydropyri din-3 - yl)amino)imidazo[ 1 ,2-c/]pyrimidin-6-yl)oxy)pyridin-2-yl)acetamide
- reaction mixture was stirred at 80 °C in microwave for 2 h.
- the reaction mixture was cooled to room temperature, poured into ice-water and extracted with ethyl acetate.
- the combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure.
- the residue was purified by flash column chromatography on silica gel (Combiflash®, 10% ethyl acetate in hexane) to afford 3.7.
- Compound 1-4 can be prepared using methods described herein, e.g., as described in the synthesis of 1-3.
- Int-1 can be used to prepare compounds 1-7, 1-9, and 1-11 using methods described herein.
- Int-2 can be used to prepare compounds 1-8, 1-10, and 1-12 using methods described herein.
- Int-3 can be used to prepare compound 1-13 using methods described herein.
- JAK2 JH1 domain-catalytic, Y1007F,Y1008F
- JAK2 JH1 domain-catalytic, Y1007F,Y1008F
- Streptavidin-coated magnetic beads were treated with biotinylated small molecule ligands for 30 minutes at room temperature to generate affinity resins for kinase assays.
- Binding reactions were assembled by combining kinases, liganded affinity beads, and test compounds in lx binding buffer (lx PBS, 0.05% Tween 20, 0.1% BSA, 1 mmol/L DTT). Test compound was prepared as 11 lx stocks in 100% DMSO and directly diluted into the assay wells. All reactions were performed in polypropylene 384-well plates in a final volume of 0.02 mL.
- Binding affinity for other kinases is determined as follows: Kinase-tagged T7 phage strains are prepared in an E. coli host derived from the BL21 strain. E. coli are grown to log-phase and infected with T7 phage and incubated with shaking at 32°C until lysis. The lysates are centrifuged and filtered to remove cell debris. The remaining kinases are produced in HEK- 293 cells and subsequently tagged with DNA for qPCR detection.
- Streptavidin-coated magnetic beads are treated with biotinylated small molecule ligands for 30 minutes at room temperature to generate affinity resins for kinase assays.
- the liganded beads are blocked with excess biotin and washed with blocking buffer (SeaBlock (Pierce), 1% BSA, 0.05% Tween 20, 1 mM DTT) to remove unbound ligand and to reduce non-specific binding.
- Binding reactions are assembled by combining kinases, liganded affinity beads, and test compounds in lx binding buffer (20% SeaBlock, 0.17x PBS, 0.05% Tween 20, 6 mM DTT). Test compounds are prepared as 11 IX stocks in 100% DMSO.
- Kds are determined using an 11-point 3-fold compound dilution series with three DMSO control points. All compounds for Kd measurements are distributed by acoustic transfer (non-contact dispensing) in 100% DMSO. The compounds are then diluted directly into the assays such that the final concentration of DMSO is 0.9%. All reactions are performed in polypropylene 384-well plate. Each has a final volume of 0.02 ml. The assay plates are incubated at room temperature with shaking for 1 hour and the affinity beads are washed with wash buffer (lx PBS, 0.05% Tween 20).
- JAK2-selective compounds Compounds that exhibit a better binding affinity for JAK2 compared to one or more other kinases are considered to be JAK2-selective compounds.
- provided compounds may be JAK2-selective over one or more of the following kinases: JAK1, JAK3, and Tyk2.
- This assay measures inhibition of JAK2-mediated pSTAT5 signaling in constitutively active essential thrombocytopenia cells carrying the V617F mutation.
- Cells are harvested from a flask into cell culture medium, and the number of cells is counted.
- the cells are diluted with culture medium and 100 pL of cell suspension (50000/well) is added into each well of a 96-well cell culture plate.
- a solution of test compound is added to the assay plate.
- the plates are covered with a lid and placed in a 37 °C 5% CO2 incubator for 4 hours. After 4 hours, the cells are spun, and the cell pellets are re-suspended with 100 pL cold PBS.
- the cells are spun again at 4 °C and 4000 rpm for 5 min.
- PBS is aspirated, and 25 pL lysis buffer (with protease and phosphatase inhibitor cocktail) is added to each cell pellet.
- the cell lysate is shaken at 4 °C for 20 min to fully lyse the cells.
- the cell lysate is spun at 4 °C and 4000 rpm for 15 min, and then the supernatant is transferred into a new plate and stored at -80 °C.
- Meso-scale discovery is used to analyze plates as follows: a standard MSD plate is coated with capture antibody in PBS (40 pL/well) and is incubated at 4 °C overnight with shaking.
- the MSD plate is washed three times with 150 pL/well of lx MSD Wash Buffer (Tris-buffered saline with 0.1% Tween® 20 detergent, TBST). The MSD plates are then blocked with 150 pL of blocking buffer (5% BSA in TBST) and shaken for 1 h at room temperature and 600 rpm. The MSD plate is washed three times with 150 pL/well of lx MSD Wash Buffer (TBST). Sample lysates are then added to MSD plates (25 pL/well) and shaken for 1 h at room temperature and 600 rpm. The MSD plate is washed three times with 150 pL/well of lx MSD Wash Buffer (TBST).
- TBST 150 pL/well of lx MSD Wash Buffer
- Detection antibody (prepared in Antibody Detection buffer, 1% BSA in lxTBST) is then added to the MSD plates, and they are shaken for 1 h at room temperature and 600 rpm.
- the MSD plate is washed three times with 150 pL/well of lx MSD Wash Buffer (TBST).
- a secondary detection antibody (prepared in Antibody Detection buffer, 1% BSA in lxTBST) is then added to the MSD plates, and they are shaken for 1 h at room temperature and 600 rpm.
- the MSD plate is washed three times with 150 pL/well of lx MSD Wash Buffer (TBST).
- MSD reading buffer (lx) is added to the plates (150 pL/well), and they are diluted from 4x with water.
- the plates are imaged using an MSD imaging instrument according to the manufacturer’s instructions.
- Preparation of Caco-2 Cells 50 pL and 25 mL of cell culture medium are added to each well of a Transwell® insert and reservoir, respectively. Then, the HTS Transwell® plates are incubated at 37 °C, 5% CO2 for 1 hour before cell seeding. Caco-2 cell cells are diluted to 6.86x105 cells/mL with culture medium, and 50 pL of cell suspension are dispensed into the filter well of the 96-well HTS Transwell® plate. Cells are cultivated for 14-18 days in a cell culture incubator at 37 °C, 5% CO2, 95% relative humidity. Cell culture medium is replaced every other day, beginning no later than 24 hours after initial plating.
- Assay Procedure The Caco-2 plate is removed from the incubator and washed twice with pre-warmed HBSS (10 mM HEPES, pH 7.4), and then incubated at 37 °C for 30 minutes.
- the stock solutions of control compounds are diluted in DMSO to get 1 mM solutions and then diluted with HBSS (10 mM HEPES, pH 7.4) to get 5 mM working solutions.
- the stock solutions of the test compounds are diluted in DMSO to get 1 mM solutions and then diluted with HBSS (10 mM HEPES and 4% BSA, pH 7.4) to get 5 pM working solutions.
- the final concentration of DMSO in the incubation system is 0.5%.
- Time 0 samples are prepared by transferring 50 pL of 5 mM working solution to wells of the 96-deepwell plate, followed by the addition of 200 pL cold methanol containing appropriate internal standards (IS). The plates are incuabted at 37 °C for 2 hours. At the end of the incubation, 50 pL samples from donor sides (apical compartment for Ap Bl flux, and basolateral compartment for Bl Ap) and receiver sides (basolateral compartment for Ap Bl flux, and apical compartment for Bl Ap) are transferred to wells of a new 96-well plate, followed by the addition of 4 volume of cold acetonitrile or methanol containing appropriate internal standards (IS).
- the plates are incubated at 37 °C for 30 minutes. 80 pL samples are removed directly from the apical and basolateral wells (using the basolateral access holes) and transferred to wells of new 96 wells plates.
- the Lucifer Yellow fluorescence (to monitor monolayer integrity) signal is measured in a fluorescence plate reader at 485 nM excitation and 530 nM emission.
- HEK293T cells are harvested from flask into cell culture medium, and then the cells are counted.
- the cells are diluted with culture medium to the desired density, and 40 pL of cell suspension is added into each well of a 384-well cell culture plate.
- the plates are covered with a lid and spun at room temperature at 1,000 RPM for 1 minute and then transferred into 37 °C 5% CO2 incubator overnight.
- Test compounds are dissolved at 10 mM DMSO stock solution. 45 pL of stock solution is then transferred to a 384 PP-plate.
- a 3-fold, 10-point dilution is performed via transferring 15 pL compound into 30 pL DMSO by using TEC AN (EVO200) liquid handler.
- the plates are spun at room temperature at 1,000 RPM for 1 minute and shaken on a plate shaker for 2 minutes. 40 nL of diluted compound is transferred from compound source plate into the cell plate by using liquid handler Echo550. After compound treatment for 48 hours, CTG detection is performed for compound treatment plates: the plates are removed from incubators and equilibrated at room temperature for 15 minutes. 30 pL of CellTiter-Glo reagent is added into each well to be detected. The plates are then placed at room temperature for 30 min followed by reading on EnVision.
- IC50 values are calculated using XLFit (equation 201).
- Stock solutions are diluted to 100 pM by combining 198 pL of 50% acetonitrile/50% water and 2 pL of 10 mM stock solution. Verapamil is used as positive control in the assay.
- Vials of cryopreserved hepatocytes are thawed in a 37 °C water bath with gently shaking. The contents are poured into the 50 mL thawing medium conical tube. Vials are centrifuged at 100 g for 10 minutes at room temperature. Thawing medium is aspirated and hepatocytes are re-suspended with serum-free incubation medium to yield -1.5 x 106 cells/mL.
- Cell viability and density are counted using a Trypan Blue exclusion, and then cells are diluted with serum-free incubation medium to a working cell density of 0.5x106 viable cells/mL.
- a portion of the hepatocytes at 0.5x106 viable cells/mL are boiled for 5 min prior to adding to the plate as negative control to eliminate the enzymatic activity so that little or no substrate turnover should be observed.
- Aliquots of 198 pL hepatocytes are dispensed into each well of a 96-well non-coated plate. The plate is placed in the incubator for approximately 10 minutes.
- the solubility sample plate is transferred to the Thermomixer comfort plate shaker and incubated at RT for 2 hours with shaking at 1100 rpm. After 2 hours incubation, stir sticks are removed using a big magnet and all samples from the solubility sample plate are transferred into the filter plate. All the samples are filtered by vacuum manifold. The filtered samples are diluted with methanol. Samples are analyzed by LC-MS/MS and quantified against a standard of known concentration in DMSO using LC coupled with Mass spectral peak identification and quantitation. The solubility values of the test compounds are calculated as follows, wherein INJ VOL is injection volume, DF is dilution factor, and STD is standard:
- test compounds and control compound are prepared in DMSO at the concentration of 200 mM, and then the working solutions are spiked into plasma. The final concentration of compound is 1 mM. The final concentration of DMSO is 0.5%.
- Ketoconazole is used as positive control in the assay. Dialysis membranes are soaked in ultrapure water for 60 minutes to separate strips, then in 20% ethanol for 20 minutes, finally in dialysis buffer for 20 minutes. The dialysis set up is assembled according to the manufacturer’s instruction. Each Cell is with 150 pL of plasma sample and dialyzed against equal volume of dialysis buffer (PBS). The assay is performed in duplicate.
- PBS dialysis buffer
- the dialysis plate is sealed and incubated in an incubator at 37 °C with 5% CO2 at 100 rpm for 6 hours.
- 50 pL of samples from both buffer and plasma chambers are transferred to wells of a 96-well plate.
- 50 pL of plasma is added to each buffer samples and an equal volume of PBS is supplemented to the collected plasma sample.
- 400 pL of precipitation buffer acetonitrile containing internal standards (IS, 100 nM alprazolam, 200 nM labetalol, 200 nM imipramine and 2 pM ketoplofen) is added to precipitate protein and release compounds.
- Samples are vortexed for 2 minutes and centrifuged for 30 minutes at 3,220 g.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La présente invention concerne des composés hétéroaryloxy triazolo-azines et imidazo-azines ainsi que des compositions de ceux-ci utiles pour inhiber JAK2.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202163226889P | 2021-07-29 | 2021-07-29 | |
US63/226,889 | 2021-07-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2023009708A1 true WO2023009708A1 (fr) | 2023-02-02 |
Family
ID=82898774
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2022/038654 WO2023009708A1 (fr) | 2021-07-29 | 2022-07-28 | Hétéroaryloxy triazolo-azines et imidazo-azines en tant qu'inhibiteurs de jak2 |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2023009708A1 (fr) |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040122237A1 (en) * | 2002-03-29 | 2004-06-24 | Payman Amiri | Substituted benzazoles and methods of their use as inhibitors of Raf kinase |
WO2004085425A1 (fr) * | 2003-03-21 | 2004-10-07 | Amgen Inc | Azoles fusionnes tels que benzimidazoles, benzoxazoles et benzothiazles 2,5-disubstitues comme inhibiteurs de kinase |
WO2005037273A1 (fr) * | 2003-10-16 | 2005-04-28 | Chiron Corporation | Benzazoles substitues et leur utilisation en tant qu'inhibiteurs de la raf kinase |
WO2008150015A1 (fr) * | 2007-06-05 | 2008-12-11 | Takeda Pharmaceutical Company Limited | Composés hétérobicycliques comme inhibiteurs de kinase |
WO2009155565A1 (fr) * | 2008-06-20 | 2009-12-23 | Genentech, Inc. | Composés triazolopyridine inhibiteurs de jak kinase et procédés |
WO2010141796A2 (fr) * | 2009-06-05 | 2010-12-09 | Cephalon, Inc. | Préparation et utilisation de dérivés de 1,2,4-triazolo[1,5a]pyridine |
US20110201605A1 (en) * | 2010-02-17 | 2011-08-18 | Karlheinz Baumann | Heteroaryl substituted piperidines |
WO2020097400A1 (fr) * | 2018-11-07 | 2020-05-14 | Dana-Farber Cancer Institute, Inc. | Dérivés d'imidazopyridine et dérivés d'aza-imidazopyridine utilisés comme inhibiteurs de la janus kinase 2 et utilisations associées |
WO2021226261A1 (fr) * | 2020-05-06 | 2021-11-11 | Ajax Therapeutics, Inc. | 6-hétéroaryloxy benzimidazoles et azabenzimidazoles en tant qu'inhibiteurs de jak2 |
-
2022
- 2022-07-28 WO PCT/US2022/038654 patent/WO2023009708A1/fr unknown
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040122237A1 (en) * | 2002-03-29 | 2004-06-24 | Payman Amiri | Substituted benzazoles and methods of their use as inhibitors of Raf kinase |
WO2004085425A1 (fr) * | 2003-03-21 | 2004-10-07 | Amgen Inc | Azoles fusionnes tels que benzimidazoles, benzoxazoles et benzothiazles 2,5-disubstitues comme inhibiteurs de kinase |
WO2005037273A1 (fr) * | 2003-10-16 | 2005-04-28 | Chiron Corporation | Benzazoles substitues et leur utilisation en tant qu'inhibiteurs de la raf kinase |
WO2008150015A1 (fr) * | 2007-06-05 | 2008-12-11 | Takeda Pharmaceutical Company Limited | Composés hétérobicycliques comme inhibiteurs de kinase |
WO2009155565A1 (fr) * | 2008-06-20 | 2009-12-23 | Genentech, Inc. | Composés triazolopyridine inhibiteurs de jak kinase et procédés |
WO2010141796A2 (fr) * | 2009-06-05 | 2010-12-09 | Cephalon, Inc. | Préparation et utilisation de dérivés de 1,2,4-triazolo[1,5a]pyridine |
US20110201605A1 (en) * | 2010-02-17 | 2011-08-18 | Karlheinz Baumann | Heteroaryl substituted piperidines |
WO2020097400A1 (fr) * | 2018-11-07 | 2020-05-14 | Dana-Farber Cancer Institute, Inc. | Dérivés d'imidazopyridine et dérivés d'aza-imidazopyridine utilisés comme inhibiteurs de la janus kinase 2 et utilisations associées |
WO2021226261A1 (fr) * | 2020-05-06 | 2021-11-11 | Ajax Therapeutics, Inc. | 6-hétéroaryloxy benzimidazoles et azabenzimidazoles en tant qu'inhibiteurs de jak2 |
Non-Patent Citations (13)
Title |
---|
"March's Advanced Organic Chemistry", 2001, JOHN WILEY & SONS |
JAFFER, T.MA, D, TRANSL. CANCER RES., vol. 5, 2016, pages S616 - S628 |
JUTZI, J.S. ET AL., HEMASPHERE, vol. 2, no. 3, 2018 |
MEYER S. C.LEVINE, R. L., CLIN. CANCER RES., vol. 20, no. 8, 2014, pages 2051 - 9 |
O'SHEA, J. J. ET AL., ANN. RHEUM. DIS., 7 April 2013 (2013-04-07) |
RODRIGUES, M. A.TORRES, T. J., DERM. TREAT., vol. 31, no. 1, 2019, pages 33 - 40 |
S. M. BERGE ET AL., J. PHARMACEUTICAL SCIENCES, vol. 66, 1977, pages 1 - 19 |
THE LANCET |
THOMAS SORRELL: "Handbook of Chemistry and Physics", 1999, UNIVERSITY SCIENCE BOOKS |
VAINCHENKER, W. ET AL., FLOOORESEARCH, vol. 7, 2018, pages 82 |
VAINCHENKER, W.KRALOVICS, R, BLOOD, vol. 129, no. 6, 2017, pages 667 - 79 |
WU, S. C. ET AL., CANCER CELL, vol. 28, no. 1, 13 July 2015 (2015-07-13), pages 29 - 41 |
YUMEEN, S ET AL., BLOOD ADV, vol. 4, no. 10, 2020, pages 2213 - 2226 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2017287553B2 (en) | Imidazopyrazinamine phenyl derivative and use thereof | |
MX2015001715A (es) | Compuestos de pirrolopirimidina novedosos como inhibidores de proteinas quinasas. | |
CA2932175C (fr) | Inhibiteurs d'itk et de jak3 3,5-(non)substitue-1h-pyrrolo[2,3-b]pyridine, 1h-pyrazolo[3,4-b]pyridine et 5h-pyrrolo[2-,3-b]pyrazine | |
US11691963B2 (en) | 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors | |
JP2009537520A (ja) | Fgf受容体キナーゼ阻害剤のための組成物および方法 | |
US11213520B2 (en) | Phenylpyrazolylacetamide compounds and derivatives as CDK8/CDK19 inhibitors | |
CA3147902A1 (fr) | Amides heterobicycliques servant d'inhibiteurs de cd38 | |
AU2020304472A1 (en) | Pyrazolone and pyrimidine compound, and preparation method and use therefor | |
US20230219986A1 (en) | Novel aminopyrimidine egfr inhibitor | |
TW202200575A (zh) | 一種免疫抑制劑、其製備方法和應用 | |
TW202400581A (zh) | 驅動蛋白kif18a抑制劑及其應用 | |
AU2021222197A1 (en) | Heteroaryl heterocyclic compounds and uses thereof | |
TW202340209A (zh) | 用於治療癌症之環狀2-胺基-3-氰基噻吩及衍生物 | |
KR20150056550A (ko) | 키나제 억제제로서의 디히드로피롤리디노-피리미딘 | |
CA3191362A1 (fr) | Compose pyrazolopyridazinone, composition pharmaceutique le contenant et son utilisation | |
US11304929B2 (en) | Tosylacetate based compounds and derivatives thereof as PHGDH inhibitors | |
CN116568687A (zh) | 杂芳基杂环化合物及其用途 | |
CA3069602A1 (fr) | Derive de formylpyridine ayant une activite inhibitrice de fgfr4, son procede de preparation et son utilisation | |
US11970494B2 (en) | 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors | |
EA029269B1 (ru) | Производные пирролопирролона и их применение для лечения заболеваний | |
WO2023009708A1 (fr) | Hétéroaryloxy triazolo-azines et imidazo-azines en tant qu'inhibiteurs de jak2 | |
WO2023009712A1 (fr) | Hétéroaryloxy thiazolo azines en tant qu'inhibiteurs de jak2 | |
WO2023009709A1 (fr) | Pyrazolo pipérazines en tant qu'inhibiteurs de jak2 | |
US11261184B2 (en) | [1,6]naphthyridine compounds and derivatives as CDK8/CDK19 inhibitors | |
WO2024148247A2 (fr) | Azaindazoles en tant qu'inhibiteurs de jak2 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22754722 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |